Early phase clinical drug development for HPV-induced disorders: novel tools and treatments by Rijsbergen, M.
 
Cover Page 
 
 
 
 
 
 
 
 
The handle http://hdl.handle.net/1887/85448 holds various files of this Leiden University 
dissertation. 
 
Author: Rijsbergen, M. 
Title: Early phase clinical drug development for HPV-induced disorders: novel tools and 
treatments 
Issue Date: 2020-02-19 
 
Melanie Rijsbergen
Early phase clinical 
drug development for 
HPV-induced disorders: 
novel tools and 
treatments
Ea
r
ly ph
a
se c
lin
ic
a
l d
ru
g
 d
evelo
pm
en
t fo
r H
PV-in
d
u
c
ed
 d
iso
r
d
er
s: n
o
vel to
o
ls a
n
d
 tr
eatm
en
ts – m
ela
n
ie r
ijsberg
en
see inside for color illustrations of chapter 3 , 4 and 5 see inside for color illustrations of chapter 1 and 3
341_Omslag_M_03.indd   1 06-01-20   14:52
Chapter 3 – Figure 1. 3D reconstruction of the twelve inch ruler (A) and wart-like object 
(B). Three-D reconstruction of the twelve inch ruler by the image reconstruction software 
(A), and the wart-like object in a 3D reconstruction with a heat-map showing the height of the 
object which is used for the 3D analysis (B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 – Figure 1. Genome organization of the Alpha papillomavirus HPV16. The 
genome is comprised of a long control region (LCR) and eight genes that are involved in the 
virus life cycle. This figure is adapted from de Sanjosé 2018 and Doorbar 2015.9,10 
 
 
Chapter 1 – Figure 2. The life cycle of a HPV infection. A diagrammatic representation of 
the skin is shown after infection with HPV. Often a micro-trauma of the epithelium allows 
the virus to infect cells in the basal layer of the epithelium (dotted arrow lines). In the basal 
epithelial cells the virions are internalized and the viral genomes are transferred to the 
nucleus (genome maintenance). The genome of the virus is replicated in the nucleus and 
hereafter the virus particles are produced and released. The involvement of the early and late 
genes is shown with the arrows next to the figure. This figure is adapted from Doorbar 2005.4 
 
Chapter 1 – Figure 3. Phylogenetic tree of human papilloma virus (HPV) demonstrating 
their evolutionary relationship. HPV types are divided in 5 different groups: Alpha (pink and 
yellow), Beta (green), Gamma (blue), Mu (purple) and Nu (lilac). The Alpha-papillomaviruses 
are subdivided as low-risk (yellow) and high-risk (pink) based on the benign or malignant 
potential of the virus, respectively. Cutaneous warts are caused by low-risk HPV types of the 
Alpha genus. Typical appearances of a common wart on the hand (left) and a plantar wart 
(right) are shown. Anogenital warts are also caused by low-risk HPV types of the Alpha genus, 
but these are phylogenetically different from the HPV types causing cutaneous warts as shown 
in the tree by the division of the branches. Anogenital warts on the penile shaft (upper) and 
under the foreskin (lower) are shown. High-risk HPV types of the Alpha genus (pink) cause 
vulvar high-grade squamous intraepithelial lesions (HSIL) with a high degree of variation in 
appearance, such as elevated hyperkeratotic white lesions (left) or red lesions (right). 
E1+E2:  Genome replication
E4:  Virus release and transmission
E5:  Evading immune response 
 and apoptosis
E6+E7:  Oncogenes
L1:  Major capsid protein
L2: Minor capsid pr tein
lcr:  Long control region
Chapter 3 – Figure 2. Three-dimensional reconstruction by stereophotogrammetry.  
A representative lesion for all three HPV-induced lesions (cutaneous warts, anogenital warts 
and vulvar HSIL) with on the left the 2D photograph, in the middle the 3D reconstruction and 
on the right the heat map showing height differences and the manual contour around the 
lesion. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 – Figure 2. Photography assessments of lesions over time. Photography of a 
patient with angenital warts and vulvar HSIL, both patients were treated with omiganan. Pre-
dose (day 0) the lesions are clearly visible. Upon treatment, the genital warts clearly resolve (a) 
and the vulvar HSIL remained the same (c). The patient of picture 2a had total clearance of the 
genital warts at EOS, but a post-inflammatory hypopigmentation has occurred at the lesion 
site. Day 0 is before start of treatment, day 84 is at the end of treatment (EOT) and day 168 is at 
the end of study (EOS). 
 
 
 
 
 
 
 
 
 
 
 
Anogenital wart (agw)
 day 0 (pre-dose) day 84 (eot) day 168 (eos) 
 
Vulvar hsil
 day 0 (pre-dose) day 84 (eot) day 168 (eos)
-4
-2
0
2
28 42
eot
70 9814
-4
-2
0
2
D
ia
m
et
er
 (m
m
) l
sm
cf
b
Placebo
Digoxin 
+ Furosemide
Digoxin
Furosemide
28 42 70 9814
eoseot eos
D
ia
m
et
er
 (m
m
) l
sm
cf
b
a b
c
Day 0 (pre dose) Day 14 Day 28 Day 42 (eot) Day 98 (eos)Day 70
Study dayStudy day
Chapter 5 – Figure 5. Histological representative cases of classical cutaneous viral 
warts. (a) Verruca vulgaris H&E low power view (50x) with architectural characteristic 
inturning of the elongated rete ridges, epidermal hyperplasia, papillomatosis, 
hypergranulosis, hyperkeratosis and columns of parakeratosis. (b) Verruca vulgaris H&E, 
detail view (200x): note koilocytes (arrowhead) and coarse granula (arrows) mostly in top 
layers (stratum granulosum). (c) H&E low power view (50x) of verruca plana with epidermal 
hyperplasia, hypergranulosis, hyperkeratosis, koilocytes in middle and upper layers. (d) 
verruca plana H&E, detail view (100x) note the absence of papillomatosis, parakeratosis and 
coarse granula. 
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lcr:  Long control region
Chapter 5 – Figure 3c. Photography assessments of a common wart of subject #6 
(digoxin+furosemide). (a) Analysis of the primary endpoint for the intention-to-treat 
population (N=79) was performed using a mixed model with treatment, time and treatment 
by time as fixed factors and subject as random factor. All statistical tests were two-tailed 
with α-level of 0.05. Results showed a statistically significant reduction of wart size in the 
digoxin+furosemide group compared to placebo (-2.5mm; 95% CI -4.9 to -0.1; p=0.04). Single 
treatment groups (digoxin vs placebo and furosemide versus placebo) showed no statistically 
significant effects (-1.5mm; 95% CI -3.9 to 0.9; p=0.21, and -1.1mm; 95% CI -3.4 to 1.3; p=0.38, 
respectively). Changes in diameter were most pronounced after EOT, as shown in Figure 3A. 
(b) In the analysis of all treated warts (N=139) a statistically significant wart size reduction 
was observed between each active treatment group and placebo (digoxin+furosemide versus 
placebo; -3.0mm; 95% CI -4.9 to -1.1; p=0.002, digoxin vs placebo -1.9mm; 95% CI -3.7 to -0.2; 
p=0.03, furosemide versus placebo -2.1mm; 95% CI -3.8 to -0.4; p=0.01). (c) A photography 
assessment of a treated wart in the digoxin+furosemide group.
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Chapter 5 – Fi ure 5. Histological representative cases of clas ical cutaneous viral 
warts. ( ) Verruca vulgaris H&E low po er view (50x) with archit ctural characteristic 
inturning of th  elongated r te ridges, e idermal hyperplasia, papillomatosis, 
hyperg anulosis, hyperkerato is and columns of parakeratosis. (b) Verruca vulgaris H&E, 
detail view (200x): note koilocytes (arrowhead) and coarse granula (arrows) mostly in top 
layers (stratum granulosum). (c) H&E low power view (50x) of verruca plan  with epidermal 
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verruca p ana H&E, detail view (100x) note the absence of apillomatosis, parakeratosis and 
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Chapter 1
introduction
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Figure 1. Genome organization of the Alpha papillomavirus HPV16. The genome is 
comprised of a long control region (LCR) and eight genes that are involved in the virus life 
cycle. This figure is adapted from de Sanjosé 2018 and Doorbar 2015.9,10  (see inside front-
cover for image in color) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The life cycle of a HPV infection. A diagrammatic representation of the skin is 
shown after infection with HPV. Often a micro-trauma of the epithelium allows the virus 
to infect cells in the basal layer of the epithelium (dotted arrow lines). In the basal epithelial 
cells the virions are internalized and the viral genomes are transferred to the nucleus 
(genome maintenance). The genome of the virus is replicated in the nucleus and hereafter 
the virus particles are produced and released. The involvement of the early and late genes 
is shown with the arrows next to the figure. This figure is adapted from Doorbar 2005.4 
 (see inside front-cover for image in color) 
E1+E2:  Genome replication
E4:  Virus release and transmission
E5:  Evading immune response 
 and apoptosis
E6+E7:  Oncogenes
L1:  Major capsid protein
L2:  Minor capsid protein
lcr:  Long control region
Human papillomavirus (HPV) infections cause a variety of epithelial lesions 
ranging from benign common warts to malignant anogenital diseases. The 
overall disease burden of HPV infections varies correspondingly from min-
imal cosmetic discomfort to highly debilitating morbidity and even mor-
tality. For the latter category the incidence of HPV-induced diseases still in-
creases, even despite preventive vaccination strategies. As an example, the 
life-time risk of acquiring a genital HPV-infection is around 80% and almost 
10% of these develop into persistent infections related to (pre)malignant dis-
eases.1,2 Current treatments of HPV-induced lesions consist of medical and 
surgical therapies that focus on lesion removal instead of eradication of the 
virus. These treatments are often associated with significant side effects and 
high recurrence rates. Therefore, there is a strong medical need for new HPV 
eliminating drugs with an acceptable side effect profile. The scope of this 
thesis is to elucidate novel pharmacological interventions for HPV-induced 
diseases by using a question-based developmental approach that includes in-
vestigation of the pharmacological effects in an early phase of drug develop-
ment.3 The emphasis of the thesis is on the development of new method-
ological tools to monitor the course of HPV-related diseases in clinical trials, 
as well as the exploration of successful biomarkers of viral load in HPV in-
fections. This introduction summarizes the biology of HPV and its different 
types, the pathophysiology of HPV-induced diseases and addresses the rel-
evance of question-based drug development and the development of new 
methodological tools and biomarkers. 
Human papillomavirus biology
Papillomaviruses are small, non-enveloped, circular, double-stranded DNA 
viruses that belong to the Papillomaviridae family and infect cutaneous and 
mucosal epithelial cells.4 The genome of the HPV is distributed into early 
genes E1-E2, E4-E7 and late genes L1 and L2 (Figure 1).5,6 The early genes E1, 
E2, E4 and E5 induce the maintenance, transformation and replication of 
the viral infection.6 A persistent infection with a high-risk HPV type can in-
duce the integration of the viral DNA into the human genome, causing over-
expression of the E6 and E7 oncoproteins and lead to (pre)malignant pro-
gression of the lesion. The late genes encode for viral capsid proteins which 
are only expressed in highly differentiated epithelial cells and lead to a high 
number of HPV copies. 
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HPV infection is about 80% and approximately 40% of female adolescents be-
come infected with a high-risk HPV type at least once.1,2,15 The prevalence of 
a high-risk infection decreases with age, being 15% in all women and 9% of all 
women above 30 years.2 The majority of these infections are transient and 
will be cleared by the immune system without causing any lesions.
This thesis describes studies performed in patients with cutaneous warts, 
anogenital warts and vulvar HSIL, being Alpha papillomaviruses-induced dis-
eases illustrative for typical low-risk (cutaneous warts and anogenital warts) 
and high-risk (vulvar HSIL) HPV-induced diseases falling within the scope of 
this thesis.
Table 1. The different human papilloma virus (HPV) groups based on their evolutionary 
relationship. The HPV types are divided in 5 different groups; Alpha (pink and yellow), 
Beta (green), Gamma (blue), Mu (purple) and Nu (lilac). The Alpha-papillomaviruses are 
subdivided as low-risk (yellow) and high-risk (pink) based on the benign or malignant 
potential of the virus, respectively. Examples of different HPV types, tissue preference and 
associated diseases are given.12,13 
 
Genus + Species Types Tissue preference Diseases
Alpha 1, 13 HPV32, HPV54 Mucosal Low-risk mucosal 
lesions
Alpha 8 HPV7 Mucosal Butcher’s wart
Alpha 10 HPV6, HPV11 Mucosal/
cutaneous
Anogenital warts, 
oral/laryngeal 
papillomas 
Alpha 9 HPV16, HPV31, HPV33 Mucosal Vulvar and cervical 
HSIL/carcinoma
Alpha 7 HPV18, HPV45 Mucosal Cervical HSIL/
carcinoma
Alpha 5, 6, 11 HPV51, HPV56, HPV34 Mucosal Cervical HSIL/
carcinoma
Alpha 2, 3, 14, 15 HPV3, HPV10 Mucosal Low-risk mucosal 
lesions, flat warts
Alpha 4 HPV2, HPV27, HPV57 Cutaneous Cutaneous warts
Beta 1-5 HPV5, HPV8 Cutaneous Skin cancer, 
epidermodysplasia 
verruciformis
Gamma 1-5 HPV4, HPV60 Cutaneous Cutaneous warts, 
epidermoid cyst
Mu 1-2 HPV1, HPV63 Cutaneous Cutaneous warts
Nu 1 HPV41 Cutaneous Cutaneous lesions
Infection with HPV requires access of the virus to cells in the basal layer, by 
micro trauma of the epithelium (Figure 2). The capsid of the virion is cleaved 
to facilitate the virus internalization.6,7 Once the virions are internalized they 
undergo endosomal transport, further uncoating, cellular sorting and subse-
quent transfer of the viral genome to the nucleus. Infection of the lower ep-
ithelial layer is followed by an initial phase of genome amplification in low 
copy numbers and maintenance of the viral genome.6 The genome amplifi-
cation is further facilitated by the upper epithelial layers which results in a 
high genome copy number. It is hypothesized that the infection of an epithe-
lial stem cell is necessary in the lesion formation process.6,8
To date, more than 207 different human papillomavirus (HPV) genotypes 
have been identified based on the DNA sequence and are divided into five 
phylogenetic groups: Alpha, Beta, Gamma, Mu and Nu.5,11 Figure 3 shows the 
five phylogenetic groups and the subdivision of Alpha papillomaviruses into 
low-risk (yellow, e.g., cutaneous and anogenital warts) and high-risk (pink, 
e.g., vulvar high-grade squamous intraepithelial lesions (HSIL)) diseases. 
Next to different life-cycle characteristics and disease associations, the 
HPV types in the different phylogenetic groups can be categorized as either 
cutaneous or mucosal genotypes based on their tissue preference (Table 1). 
The majority of HPV infections manifest themselves as an asymptomat-
ic infection of the cutaneous or mucosal epithelium, although self-limiting 
benign growth is also frequently observed. Most HPV types belong to the 
Alpha papillomaviruses group and these HPV types cause mucosal and cu-
taneous lesions. This group includes the HPV types that primary cause cu-
taneous warts and also the genitally transmitted HPV types. The latter men-
tioned viruses are the most common sexually transmitted pathogens world-
wide and some of these are associated with the development of cancer.4 The 
Beta papillomaviruses infect the cutaneous epithelia and mostly cause inap-
parent or latent infections but can also cause non-melanoma skin (pre)ma-
lignancies.5 The Gamma, Mu and Nu papillomavirus mostly causes benign 
cutaneous lesions.5The subdivision of HPV types into low-risk and high-risk 
depends on their carcinogenicity, i.e. the benign or malignant potential of 
the virus.14 Infection by low-risk HPV types is asymptomatic or can cause be-
nign lesions. However, persistent infection with high-risk types can cause 
(pre)malignant anogenital lesions.5 The lifetime risk of acquiring a genital 
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located on foot soles, and common warts, located on all other skin locations 
(Figure 1). The diagnosis of cutaneous warts is based on clinical observations. 
Depending on the HPV-genotype and clinical location, the clinical appear-
ance of common and plantar warts differs but most warts present as hy-
perkeratotic papules or plaques. Common warts are mostly elevated, scaly, 
rough and skin-colored papules or nodules, while plantar warts are mostly 
thick, hyperkeratotic, papules with capillary thrombosis.
The most frequently used treatments for cutaneous warts are cryothera-
py, salicylic acid, ablation and surgical excision, aimed at destruction of the 
infected tissue. The efficacy, recurrence rates and side effects of these ther-
apies are depicted in Table 2. The most commonly used therapy is cryother-
apy which consists of the use of liquid nitrogen at a temperature of -196°C 
to create an area of necrosis below and around the wart.28,29 Salicylic acid 
causes chemical ablation of the wart. Ablation with a laser or electrocautery 
has comparable efficacy rates as surgical excision, however is not often used 
because of the invasive nature and side effects.28
Table 2. Efficacy rates and side effects of the most common treatments for cutaneous 
warts. 
 
Treatment Efficacy rate Side effects 
Cryotherapy 29-51%29-31 Pain, blistering, scarring, irritation, pigmentation, crust 
formation30
Salicylic acid 16-35%29-31 Irritation, pain, blistering, bleeding, pigmentation30
Ablation 75-100%29,31 Pain, scarring, crust formation, irritation29
Anogenital warts
Anogenital warts (AGW), caused by low-risk HPV types such as HPV6 and 11, 
are highly contagious and are the most common sexually transmitted viral 
disease worldwide with an incidence of 160-289 per 100.000.1,32-34 Genital 
warts generally cause minor symptoms such as pruritus and irritation, but 
most patients report a high psychological burden from the disfiguring nature 
of the warts and concerns about infecting sexual partners.35,36 Two prophy-
lactic vaccines are available against HPV, namely 2-valent papillomavirus vac-
cine (Cervarix®) and 4-valent papillomavirus vaccine (Gardasil®). Cervarix® 
includes the high-risk HPV types 16 and 18 and Gardasil® includes next to HPV 
16 and 18 also the low-risk HPV types 6 and 11. A 9-valent papillomavirus vac-
cine (Gardasil-9®) recently became available and contains 5 other high-risk 
Figure 3. Phylogenetic tree of human papilloma virus (HPV) demonstrating their 
evolutionary relationship. HPV types are divided in 5 different groups: Alpha (pink and 
yellow), Beta (green), Gamma (blue), Mu (purple) and Nu (lilac). The Alpha-papillomaviruses 
are subdivided as low-risk (yellow) and high-risk (pink) based on the benign or malignant 
potential of the virus, respectively. Cutaneous warts are caused by low-risk HPV types of 
the Alpha genus. Typical appearances of a common wart on the hand (left) and a plantar 
wart (right) are shown. Anogenital warts are also caused by low-risk HPV types of the Alpha 
genus, but these are phylogenetically different from the HPV types causing cutaneous 
warts as shown in the tree by the division of the branches. Anogenital warts on the penile 
shaft (upper) and under the foreskin (lower) are shown. High-risk HPV types of the Alpha 
genus (pink) cause vulvar high-grade squamous intraepithelial lesions (HSIL) with a high 
degree of variation in appearance, such as elevated hyperkeratotic white lesions (left) or 
red lesions (right). (see inside front-cover for image in color)
Cutaneous warts
Cutaneous warts are a common benign skin condition with an estimated 
prevalence of 3-13% in the general population in the Western world.16 Most 
people are affected by cutaneous warts at some time point in their life.16-19 
The vast majority (>80%) of cutaneous warts in the general population is 
caused by HPV1, 2, 27 and 57.20-25 Two-third of all warts show spontaneous 
regression within two years after diagnosis. Although cutaneous warts are 
benign and usually resolve spontaneously, they cause physical and psychoso-
cial discomfort.26,27 Cutaneous warts can be subdivided into plantar warts, 
Early phase clinical drug development for HPV-induced disorders14 15chapter 1 – introduction
is in 90% of the cases caused by HPV type 16.57 The incidence of vulvar HSIL is 
2-5 per 100.000 but the incidence is rising and young women in their 30s and 
40s are most often affected.58,59 The majority of patients suffer from long-
lasting and severe symptoms like pruritus or pain and the disease is associ-
ated with a high psychosocial burden and sexual dysfunction.60 Vulvar HSIL 
has a malignant potential of 3-5% when treated, but when left untreated inci-
dence may increase up to 9%.57,61,62 Only up to 1.5% of vulvar HSIL lesions are 
reported to regress spontaneously.61,62 
Vulvar HSIL has a highly variable appearance on clinical examination and 
may therefore be difficult to diagnose (Figure 3). Diagnosis always has to be 
confirmed by histopathological analysis. The lesions can be unifocal or mul-
tifocal, can present as plaques or papules and may be white, brown or red. 
The lesional skin can be thickened (hyperkeratosis), split (fissures) or ulcer-
ated. Vulvar HSIL is often a multicentric disease, therefore it is important to 
examine the cervix, vagina and anus as well.63
The aim of vulvar HSIL treatment is symptom relief, restore normal anato-
my and prevention of malignant progression. Considering the low malignant 
potential of the disease, expectative management in combination with close 
follow-up can be considered if patients have no severe symptoms and there 
is no suspicion of invasive disease. Treatment options for vulvar HSIL are sur-
gical excision, ablation (laser therapy) and imiquimod (Table 4). 
Table 4. Efficacy and recurrence rates and side effects of the treatments for vulvar 
HSIL. 
 
Treatment Efficacy  
rate
Recurrence 
rate
Side effects
Excision Not reported 51%60,64 Disfiguring, pain64,73
Laser therapy 75%62,74-76 51%60,64 Not reported
Imiquimod 51-
58%64,65,67,77
11-16%65,66 erythema, oedema, pain, erosion/ulceration, 
fatigue, headache, muscle pain64-67,69,77
Cidofovir 46%69 6%70 Pain, ulcera, fatigue, headache, muscle pain69
Further, the treatment is usually associated with psychosocial and sexual 
burden for the patient. Ablative techniques such as laser therapy offer in-
creased precision and better cosmetic results and are as efficacious as local 
excision.64 Surgical interventions aim to remove (excision) or destroy (laser) 
visible lesions, but do not eliminate the virus, while vulvar HSIL is caused by a 
persistent HPV infection. Therefore, there are often positive tumour margins 
HPV types (31, 33, 45, 52, and 58) next to HPV 16 and 18. Since 2008, the Dutch 
national immunisation programme included the Cervarix® vaccine for girls 
aged 12-13. The success rate of immunisation is rather low as the coverage is 
only 45%.37 In Australia the Gardasil® vaccine is included in the national im-
munisation programme and this has resulted in a dramatic reduction of the 
incidence of genital warts with almost 90%.38 The diagnosis of AGW is a clini-
cal diagnosis and no additional research, i.e. biopsy, is necessary. AGW can ap-
pear as solitary lesion, in clusters or as plaques and can be flat, dome-shaped, 
keratotic, pedunculated or cauliflower-shaped (Figure 3). 
Current therapeutic options for AGW can be divided into topical therapeu-
tical agents (podophyllotoxin, imiquimod) and surgical removal (cryotherapy, 
excision, electro surgery, laser ablation). Podophyllotoxin is a substance ob-
tained from the rootstock of the may apple plant and causes cell death and de-
struction of the wart. Imiquimod is an immunomodulator which causes acti-
vation of different cytokines, particularly interferon-alpha. The efficacy and 
recurrence rates and side effects of these therapies are depicted in Table 3.
Table 3. Efficacy and recurrence rates and side effects of the most common 
treatments for anogenital warts. 
 
Treatment First/
second line
Efficacy  
rate 
Recurrence 
rate
Side effects
Podophyllotoxin First 45-48%39-42 4-38%41,43 Local inflammation or 
irritation, erosion, burning, 
pain, itching44-46
Imiquimod 5% First 27-54%47-49 13-19%48,49 Erythema, erosion, itching, 
burning sensation46,49
Cryotherapyw First 27-88%50-53 21-40%51,52 Pain, ulceration, scarring, 
irritation, pigmentation51,52
Surgical excision First/second 35-72%54,55 19-29%54,55 Pain, scarring, crust 
formation46,55
Electro surgery Second 61-94%51,56 22%51,56 Pain, scarring, irritation46,51
Laser therapy Second 23-52%29,46 60-77%46 Pain, scarring, crust 
formation46
Vulvar high-grade squamous intraepithelial 
lesion
Vulvar high-grade squamous intraepithelial lesion (HSIL), previously known 
as usual vulvar intraepithelial neoplasia (uVIN), is a chronic premalignant vul-
var skin disorder caused by a persistent high-risk HPV infection. Vulvar HSIL 
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The clinical development success rate, i.e. the likelihood that an experimen-
tal compound investigated in a phase 1 study is approved, was 9,6%, based 
on data from clinical trials performed in all disciplines from 2006 to 2015.79 
The transition success rate from phase 1 to 2 was 63.2% and from phase 2 to 3 
30.7%.79 Following the traditional four clinical phases of drug development, 
most early phase studies on new compounds explore safety and tolerability 
rather than human pharmacology of the specific drug.80 The low clinical de-
velopment success rate of approximately 1 out of 10 suggests that the early 
prediction of the efficacy and safety of a new compound is of crucial impor-
tance. Early signaling of limited efficacy could halt the further development 
of a compound which can save time and resources. However, the pharma-
cological effects of a new drug are often investigated in later stages of clin-
ical drug development. Question-based development is a new approach in-
tegrating the evaluation of the pharmacological effects in an early phase of 
drug development.3 By using this approach, specific questions guide the in-
vestigation of pharmacodynamics of a compound in an early stage of devel-
opment. Questions obviously should be tailored to the compound type and 
indication(s) based on relevancy, but can generally be divided in 5 questions:3 
1 Does the drug get to the site of action? 
2 Does the compound cause its intended pharmacological/ functional 
effect(s)?
3 Does the compound have beneficial effects on the disease or its 
pathophysiology?
4 What is the therapeutic window of the drug?
5 How do the sources of variability in drug (e.g. dose, pharmacokinetics, 
and pharmacodynamics) response in the target population affect the 
development of the product?
It is essential to utilize the most appropriate methodology to answer these 
questions. Biomarkers are biological measures of pharmacodynamic drug ef-
fects. According to the World Health Organization, a biomarkers is ‘any sub-
stance, structure, or process that can be measured in the body or its products 
and influence or predict the incidence of outcome or disease’.81 The use of 
biomarkers in an early phase of drug development is of crucial importance 
to optimize development time and resources. A biomarker refers to a broad 
subcategory of medical signs of clinically significant patient outcomes that 
can be accurately and reproducibly measured.82 
or still presence of HPV infection in the surrounding tissue after surgical in-
tervention, resulting in a high number of recurrence and residual lesions of 
up to 40%.64-66 Medical treatments have the advantage that there is mini-
mal disruption of the anatomy compared to surgical interventions. The most 
commonly used medical treatment is imiquimod which was developed and 
licensed for anogenital warts but has also shown to be effective in vulvar 
HSIL.66-68 Imiquimod is an immunomodulator that destroys abnormal cells 
by enhancement of the immune response of the body. Other treatments are 
cidofovir, photodynamic therapy and therapeutic vaccination. Cidofovir is 
an antiviral therapy and can be used as a local treatment for vulvar HSIL. A 
recent randomized clinical trial in 180 subjects performed to compare treat-
ment with cidofovir and imiquimod in vulvar HSIL patients showed compa-
rable efficacy and less recurrences in the cidofovir group.69,70 Photodynamic 
therapy is based on light-induced oxidation reactions which lead to tissue ne-
crosis and has the advantage that it is well tolerated and that the anatomy of 
the vulva is preserved.71 Photodynamic therapy has been evaluated in small 
samples showing varying results in terms of efficacy.64 Therapeutic vaccina-
tion with a synthetic peptide targeting specific HPV16 has shown to induce 
clinical responses.72 Further investigation to evaluate the effect in treating 
vulvar HSIL is needed. Prophylactic vaccination against HPV has shown to re-
duce the risk of HPV-related diseases including vulvar HSIL.64 The option of 
treatment differs per patient and depends on several factors such as location 
of the lesions, uni- or multifocality, comorbidity, previous treatment and ob-
viously patient and physician preference.
Development of novel therapeutics with new 
methods and biomarkers
Using the information on registered clinical trials as available in the trial reg-
istration ‘clintrials.gov’, 501 clinical trials for HPV-induced diseases were per-
formed in the last decade. Of these studies, 79 were phase 1 trials, 125 phase 2, 
83 phase 3, 42 phase 4, and 204 not assigned to a clinical phase. In July 2019, 
208 clinical trials in HPV-induced diseases are executed according to the in-
tegrity database of Clarivate Analytics.78 Of these trials, 80 are randomized 
and 55 are double-blind and placebo-controlled. These high numbers indicate 
the medical need for the development of new compounds for HPV-induced 
diseases. A likely explanation is that current treatments are not sufficient 
given their low efficacy and high recurrence rates. 
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Outline of this thesis
This thesis describes studies that address different aspects of early clinical 
phase drug development in three different HPV-related diseases. This the-
sis is divided into two parts: section 1 describes the development and use of 
novel tools in clinical drug development and section 2 focuses on early phase 
clinical studies examining safety, tolerability, pharmacodynamic and effica-
cy parameters of new topical compounds with high pre-clinical potential for 
the treatment of HPV-induced diseases. 
Section 1 Tools and biomarkers in early phase clinical trials 
for HPV-induced diseases
The clinical trials in this thesis employed new tools and biomarkers for three 
types of HPV-induced diseases (CW, AGW and vulvar HSIL) in an early phase 
of drug development with use of the question-based drug development ap-
proach. Section 1 entails a thorough characterization of the implement-
ed tools, including valid information about treatment adherence, (adverse) 
events and symptoms. Chapter 2 describes the development, implementa-
tion and evaluation of an electronic diary to measure treatment adherence 
and patient-reported outcomes. Chapter 3 entails the technical and clinical 
validation of a stereophotogrammetric 3D camera system. 
Section 2 Novel topical treatments for HPV-induced diseases
Section 2 describes the evaluation of two new topical compounds for HPV-
induced diseases: i) omiganan, a small peptide known for its antimicrobial 
functions which has shown in vitro antiviral and immunomodulatory activity, 
and ii) ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide 
which has shown in vitro antiviral activity. Chapter 4 describes the results of 
two clinical trials using omiganan in patients with AGW and vulvar HSIL. The 
purpose of these trials was to assess the safety of omiganan and to explore 
pharmacodynamics and efficacy of omiganan in these diseases. In Chapter 
5 safety, pharmacodynamics and efficacy of topical ICVT are investigated in 
patients with cutaneous warts. Chapter 6 presents the safety and efficacy of 
topical ICVT in patients with AGW in a randomized, vehicle-controlled trial. 
     Chapter 7 summarizes and discusses the overarching findings of these 
studies as well as future perspectives on drug development in HPV-induced 
diseases. This chapter includes a critical evaluation of the process of drug de-
velopment and of novel tools and biomarkers in early phase clinical trials in 
HPV-induced diseases. 
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Introduction
Treatment adherence is the degree to which patients take their medications 
as prescribed or as instructed by their treating physician and is defined as 
taking ≥80% of the prescribed medicines.1-7 It is known that adherence to 
long-term therapy for chronic illnesses in developed countries is only ap-
proximately 50% and adherence to topical treatments is even poorer than 
oral treatments.5,8 To estimate the clinical efficacy of drugs and to exam-
ine new drugs in clinical trials, treatment adherence is of main importance. 
Safety, pharmacodynamics and efficacy can only be adequately assessed and 
interpreted if patient data on treatment adherence is available. The impact 
of poor adherence varies across numerous chronic skin disorders.9,10 For in-
stance, non-adherence to topical regimens leads to increased scores on the 
six area six sign atopic dermatitis (SASSAD) severity scale, indicating the dis-
ease severity in patients with atopic dermatitis.11 For this reason, increasing 
adherence may even have a larger impact on patient-reported outcomes than 
the improvement of the treatment itself.5 
Whereas good insight in the treatment adherence and symptoms of the 
patient is essential, patient-reported outcome measures are often recorded 
during visits and by use of paper diaries. This requires a good memory of 
the patient and depends on translation by the doctor / researcher which can 
both lead to erroneous interpretation and over or underreporting of medi-
cation use or symptoms. Paper diaries have a high recall bias, a low-to-mod-
erate adherence rate and a limited reliability and are therefore considered as 
inappropriate to reliably measure treatment adherence.12-16 Advancements 
in technology have enabled the widespread use of electronic diaries (e-dia-
ries) for both the monitoring of patient outcomes and the improvement of 
treatment adherence in clinical trials.13,17 In 2018, Svendsen et al. performed 
a randomized, controlled trial with a smartphone application for currently 
used topical treatment in patients with psoriasis and showed an improved 
short-term treatment adherence of 27% more adherence than the non-inter-
vention group.3
The purpose of this study was to investigate the utility of an e-diary in 256 pa-
tients with various skin diseases participating in six clinical trials. In this study, 
treatment adherence and patient-reported outcomes were measured by an e-
diary in six clinical trials on newly investigated topical drugs. Additionally, pa-
tient perception of usefulness and acceptability of the e-diary was evaluated. 
 
Abstract
Background Assessment of treatment effects in clinical trials requires 
valid information on treatment adherence, adverse events and symptoms. 
Paper-based diaries are often inconvenient and have limited reliability, par-
ticularly for outpatient trials. 
Objectives To investigate the utility of an electronic diary (e-diary) appli-
cation for patients with skin diseases in outpatient clinical trials. 
Methods An e-diary application was developed and technically validated. 
Treatment adherence as defined as topical administration by the patient and 
patient-reported outcomes, i.e. pain and itch, were evaluated by the e-diary 
in six clinical trials on newly tested topical drugs. Additionally, the propor-
tion of patients capturing the applied topical drug by camera and filling in the 
pain and itch scores as defined as e-diary adherence, patients’ perception of 
usefulness and acceptability of the e-diary were evaluated. 
Results Treatment adherence rates of the included 256 patients were 
high (median 98%, range 97-99%). E-diary adherence was also high with a me-
dian of 93% (range 87-97%) for capturing the applied drug by camera, 89% 
(range 87-96%) and 94% (range 87-96%) for entering respectively the itch and 
pain score. Daily symptom scores provided good insights in the disease bur-
den and patients rated the e-diary as good to excellent with respect to user 
acceptability. 
Conclusions  The results suggest that the e-diary is an excellent way to 
ensure proper treatment administration, indicated by both the high user ac-
ceptability scores and high treatment adherence. Moreover, the e-diary may 
also be valuable for frequent and reliable monitoring of patient-reported out-
comes in daily clinical practice.
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E-diary adherence
E-diary adherence was positive if the e-diary was used as intended, i.e. a pic-
ture and symptom scores were entered in the e-diary for one specific day. 
E-diary adherence was expressed as a percentage and was measured by divid-
ing the total number of actual entries (present pictures and/or NRS scores) by 
the expected entries in the entire treatment period as defined per protocol. 
Patient-reported outcomes
Severity ratings of the disease or treatment-related symptoms pain and itch 
were assessed daily by a numeric rating scale (NRS) in the e-diary. The NRS 
was selected to assess pain and itch intensity once daily on a scale from 0 to 
100 (0: no pain/itch and 100: worst pain/itch possible), if applicable, see Table 
1. The symptom assessments were used to visualize the course of symptoms 
during the diseases and only patients who received placebo treatment were 
included in these analyses. 
User acceptability of the e-diary
At the end of the treatment period, all patients were asked to fill out a 14-
item questionnaire (in Dutch) regarding their experience using the e-diary 
(Supplemental Information, questionnaire translated to English). The ques-
tionnaire consisted of multiple-choice questions and Likert-type scales re-
garding general user experience, technical aspects of the e-diary and adher-
ence. Two open-ended questions allowed patients to report the strengths 
and weaknesses of the e-diary and to fill in any comments or suggestions. 
Data analysis
Descriptive analyses and visualization were performed using IBM SPSS (ver-
sion 23, IBM Corporation, Armonk, New York, USA) and GraphPad Prism 
(version 6.05 for Windows, GraphPad Software, La Jolla, California, USA). 
Adherence was described in percentage and as the median percentage for 
all studies together.
Materials and methods
Subjects and design
From December 2014 to March 2018 six randomized, double-blind, place-
bo-controlled clinical trials were performed including various skin diseas-
es. Two different topical formulations were examined in cutaneous warts 
(CW), atopic dermatitis (AD), genital warts (GW) and vulvar high-grade squa-
mous intraepithelial lesions (HSIL). The Declaration of Helsinki was the guid-
ing principle for trial execution and all subjects gave informed consent be-
fore any procedure. The studies were approved by the Dutch Medical Ethics 
Committee (“Stichting Beoordeling Ethiek Biomedisch Onderzoek”, Assen, 
the Netherlands). The clinical efficacy and safety results of these studies have 
been or will be reported elsewhere.18-21
E-diary application
An iOS application was developed using Xcode 7 and Objective-C according 
to pre-defined User Requirement Specifications and subsequently techni-
cally validated using pertaining guidelines (see supplemental Figure). The 
application was installed on an iPod Touch or iPhone. The patients received 
oral, paper and digital (in the e-diary) instructions regarding the use of the 
e-diary. The subjects were instructed to take pictures of the amount of the 
topical drug applied using the integrated camera. A maximum of four sched-
uled e-diary notifications were repeated every 30 minutes until the picture 
was taken. Subjects were instructed to apply the drug daily and to directly 
answer questions about patient-reported outcomes. Data was saved and se-
curely transferred to the on-site server using encryption the following day. 
Treatment adherence
Treatment adherence (i.e. actual administrations divided by the expected ad-
ministrations) was measured by evaluating whether a patient had applied the 
topical drug, based on the presence of a picture in the e-diary or if absent (i.e. 
when for instance a technical issue occurred) after consultation of the pa-
tient. Expected entries were based on the number of patients and treatment 
days and calculated with the formula: number of patients times the amount 
of entries per day times treatment period in days.
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The median e-diary adherence, i.e. the proportion of patients capturing the 
applied topical drug by camera, was 93% (range 87% - 97%), see Table 3. The 
main reasons for not filling in the e-diary were either technical (empty de-
vice battery, no possibility of data entry after midnight) or patients forgot to 
take the photograph before application of the topical drug. The mean over-
all adherence of filling in the NRS for itch and pain was 90% for all trials to-
gether, see Table 4.
Table 2. Treatment adherence.
 Trial Expected 
admins1
Actual 
admins2
Overall treatment 
adherence3
Number of subjects with 
≥80% treatment adherence
1 (CW) 3280 3187 97% 79 / 80 (99%)
2 (AD) 1013 993 98% 35 / 36 (97%)
3 (AD) 4318 4233 98% 79 / 80 (99%)
4 (GW) 1960 1942 99% 24 / 24 (100%)
5 (GW) 1008 998 99% 24 / 24 (100%)
6 (vulvar HSIL) 1020 1009 99% 12 / 12 (100%)
Overall mean 12599 12360 98% 253 / 256 (99%)
Median (range) 98% (97-99%) 100% (97-100%)
1: Expected administrations of study drugs based on number of patients and treatment days (Number of 
patients x treatment period in days). / 2: Actual administrations based on photographs imported via the 
e-diary and recall of administration asked via mail or phone. / 3: Treatment adherence is the percentage 
of actual admins divided by the expected admins. / CW= cutaneous warts, AD= atopic dermatitis, GW= 
genital warts, HSIL= high-grade squamous intraepithelial lesion
Table 3. E-diary adherence. 
 Trial Expected 
entries1
Actual 
entries2
e-diary 
adherence3
Number of subjects with ≥80% 
e-diary adherence
1 (CW) 3280 3187 97% 79 / 80 (99%)
2 (AD) 1013 963 95% 35 / 36 (97%)
3 (AD) 4318 3958 92% 72 / 80 (90%)
4 (GW) 1960 1710 87% 17 / 24 (71%)
5 (GW) 1008 963 96% 23 / 24 (96%)
6 (vulvar HSIL) 1020 907 89% 11 / 12 (92%)
Overall mean 12599 11695 93% 237 / 256 (93%)
Median (range) 93% (87-97%) 94% (71-98%)
1: Expected entries of images in e-diary based on number of patients and treatment days (Number of 
patients x treatment period in days) / 2: Actual entries are the imported images of topical drug amount / 
3: e-diary treatment adherence is the percentage of actual entries divided by the expected entries / CW= 
cutaneous warts, AD= atopic dermatitis, GW= genital warts, HSIL= high-grade squamous intraepithelial 
lesion
Results
Patient characteristics
The use of the e-diary was evaluated in 256 patients in all treatment arms, 
including placebo (Table 1). The patient population in this study was the sum 
of patients enrolled and analyzed in the six trials, as there were no patients 
loss to follow up. Patients included in the trials received financial incentives. 
Treatment and e-diary adherence
The overall median treatment adherence, i.e. the proportion of patients ap-
plying the topical drug, was 98% (Table 2). This was very consistent in the dif-
ferent trials indicated by a narrow range of mean adherence of 97-99%. 
Table 1. Clinical characteristics of patients participating in the six clinical trials. Age 
is shown as mean in years. Sex is described as number of patients. Treatment period is 
described in weeks. The e-diary was filled in during the entire treatment period.  
 
Trial 
number
1 2 3 4 5 6 
Trial ID 
(NCT)
02333643 02456480 03091426 02849262 03334240 02596074
Disease Cutaneous 
warts
Atopic 
dermatitis 
Atopic 
dermatitis
Genital 
warts 
Genital 
warts
Vulvar HSIL
N 80 36 80 24 24 12
Age (SD) 25.8 (10.6) 24.9 (7.8) 24.4 (6.5) 34.4 (11.6) 30.8 (10.6) 49.8 (11.0)
Female 49 (61%) 27 (75%) 44 (55%) 9 (38%) 5 (20.8%) 12 (100%)
Male 31 (39%) 9 (25%) 36 (45%) 15 (63%) 19 (79.2%) 0 (0%)
Treatment ICVT Omiganan Omiganan Omiganan ICVT Omiganan
Dose 
strength
Digoxin + 
furosemide, 
digoxin, 
furosemide
1%, 2.5% 1%, 1.75%, 
2.5%
2.5% Digoxin + 
furosemide
2.5%
Active: 
placebo
1:1:1:1 1:1:1 1:1:1:1 2:1 3:1 2:1
Treatment 
period 
(weeks)
6 4 4 12 6 12
Regimen 
treatment 
Once daily Once daily Twice daily Once daily Once daily Once daily
NRS pain - - - Once daily Once daily Once daily
NRS itch - Twice daily Twice daily Once daily Once daily Once daily
NRS= numeric rating scale, ICVT= ionic contra-viral therapy, HSIL= high-grade squamous intraepithelial 
lesion
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friendly mainly because of its simplicity. Some patients experienced prob-
lems with filling in the e-diary before midnight and also suggested to consid-
er developing the e-diary also for android-based operating systems.
Figure 1. Symptoms itch (a) and pain (b) over time as monitored with the e-diary of 
patients in the placebo group. The symptoms itch and pain are monitored by using a 
numerical rating scale (NRS) from 0 to 100 (0 no pain/itch and 100 worst pain/itch). Per 
study day the mean itch of all subjects is shown +SD. 
AD= atopic dermatitis (N=32), GW= genital warts (N=14), HSIL= high-grade squamous intraepithelial lesion 
(N=4)
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Table 4. Adherence of NRS of itch and pain. In patients with atopic dermatitis, itch was 
assessed twice daily.
Itch Pain
 Trial Expected 
entries1
Actual 
entries2
NRS 
adherence3
Expected 
entries1
Actual 
entries2
NRS 
adherence3
2 (AD) 3192 2845 89% N.A. N.A. N.A.
3 (AD) 4480 3909 87% N.A. N.A. N.A.
4 (GW) 2016 1759 87% 2016 1760 87%
5 (GW) 999 962 96% 999 962 96%
6 (vulvar HSIL) 1020 957 94% 1020 957 94%
All studies 11707 10432 89% 4035 3679 91%
Median (range) 2016 1759 89% (87-96%) 1020 962 94% (87-96%)
1: Expected entries pain/itch scores based on patients and treatment days (Number of patients x treatment 
period in days) / 2: Actual pain/itch scores entered in the e-diary / 3: NRS pain/itch adherence is the 
percentage of actual entries divided by the expected entries / CW= cutaneous warts, AD= atopic dermatitis, 
GW= genital warts, HSIL= high-grade squamous intraepithelial lesion, N.A.= not applicable
Patient-reported outcomes
Patients with AD experienced more severe itch with an higher inter-patient 
variability compared to patients with GW and vulvar HSIL (Fig 1a). The inter-
patient variability of pain in the GW and vulvar HSIL trials was also minimal 
and most patients (10/14 and 2/4, respectively) experienced no pain (Fig. 1b). 
When examining the intra-patient variability of itch in the AD patients, there 
was an extensive variability in itch scores in course of disease during the 4 
weeks but also between the morning and evening scores (data not shown). 
There was a minimal intra-patient variability of pain and itch in the GW and 
vulvar HSIL trials (data not shown). 
User acceptability of the e-diary
A total of 249 (97%) patients completed the evaluation form (Table 5). In gen-
eral, the e-diary was rated good to excellent by 89% of the patients and the us-
er-friendliness was experienced as being good to excellent by 94% of the pa-
tients. Most patients (84%) reported that it took less than 5 minutes per day 
to use the e-diary. Of all patients, 67% never experienced any error and 23% 
of the patients reported a technical problem once or twice, i.e. empty device 
battery. In the open-ended questions regarding the strengths and weakness-
es of the e-diary, most patients commented that they found the e-diary user 
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Adherence N %
How do you estimate the 
burden of using the app 
compared to a paper diary? 
The app is..
Much less work 146 59%
Less work 56 23%
Similar work 15 6%
More work 8 3%
Much more work 8 3%
I do not know 13 5%
What do you prefer to use  
for subsequent studies?
E-diary 229 93%
Paper diary 4 2%
I do not know 13 5%
N= sum of all patients of all studies.
Discussion
This study is the first to show that a mobile e-diary application enhances the 
monitoring of patient-reported outcomes and is associated with a high treat-
ment adherence in patients with skin disorders in an outpatient clinical trial 
setting. Overall, patients appreciated the e-diary and reported that the appli-
cation was easy to use. 
The observed treatment adherence in the current study was high com-
pared to previously reported low adherence rates for topical treatment, i.e. 
up to 80% of psoriasis patients are classified as non-adherent and also adher-
ence in atopic dermatitis patients is very poor.5,8,22 However, before we draw 
convincing conclusions, there are a number of considerations that should 
be taken into account. At first, patients might have felt more responsible or 
obliged to be adherent due to a combination of our reminder strategy (i.e. 
patients received a second reminder when they did not correctly fill in the 
e-diary) and the financial incentive received. Second, we did not take the ef-
ficacy or tolerability of the drug into account, which could have influenced 
the adherence rate. 
An additional limitation of our study is the lack of a head-to-head compar-
ison with a paper diary. However, previous studies have already shown that 
paper diaries yield a much lower adherence, for instance Stone et al. found 
that the actual adherence of filling in pain scores with a paper diary was only 
11% while adherence with an e-diary was as high as 94%.13 
When interpreting the treatment adherence rates, it is important to ad-
ditionally consider the trial protocol guidelines and their relation with real 
world clinical practice. The e-diary adherence in trial 4 (GW) was lowest with 
Table 5. Evaluation of e-diary 
General user experience N %
How user-friendly was the 
app?
Excellent 108 43%
Good 126 51%
Average 11 4%
Fair 2 1%
Poor 2 1%
In general, how would you  
rate the app?
Excellent 63 25%
Good 159 64%
Average 20 8%
Fair 5 2%
Poor 1 0%
How much time did it take  
to use the app each day? 
1-5 min 209 84%
5-10 min 37 15%
10-15 min 2 1%
15-20 min 0 0%
>20 min 1 0%
How were the instructions 
given? 
Excellent 130 52%
Good 110 44%
Average 9 4%
Fair 0 0%
Poor 0 0%
Technical aspects N %
How often did technical 
problems occur (iPod, App  
or Camera)?
Never 165 67%
1-2 times 57 23%
3-4 times 12 5%
5-10 times 9 4%
>10 times 5 1%
How would you rate the photo 
function of the app?
Excellent 67 27%
Good 117 47%
Average 53 21%
Fair 8 3%
Poor 2 1%
How would you rate the 
reminder-function on the app?
Excellent 46 19%
Good 80 33%
Average 79 32%
Fair 39 16%
Poor 2 1%
Did the reminder function 
support you to apply the gel 
on time?
Definitely 105 43%
Maybe 52 21%
No 90 36%
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87%, as patients experienced problems when applying the topical drug on a 
specific calendar day. As demanded by the study protocol of a well-controlled 
trial the time window for application was set at midnight, which was unfea-
sible for some patients. Therefore the time window in the study protocol in 
trial 5 (GW) was extended, which resulted in an improvement of e-diary ad-
herence from 87% to 96%. The e-diary adherence in the trial involving pa-
tients with vulvar HSIL was marginally lower (89%) than in other trials, main-
ly caused by one subject who showed a very low treatment adherence of 30% 
due to not understanding the e-diary and device. It should be noted that the 
higher age of this population and lack of experience with mobile applica-
tions might have been a limiting factor. This is a clear indication that mobile 
apps do not provide a one-fits-all solution but that the use of an application 
needs to be carefully considered per specific age group and additional train-
ing may be required.
Altogether, we believe that our results indicate that this mobile e-diary 
platform can be used for the assessment of safety, efficacy and patient-re-
ported outcomes in clinical trials in the future. We hypothesize that the re-
minder function of the e-diary does improve treatment adherence of pa-
tients in the six trials and can be applied to prevent under- and overdosing of 
topical treatments, as previously published results indicate that 67%–95% of 
the patients using topical treatments underdose their medication.23,24 The 
e-diary will also enable the monitoring of disease-specific patient-reported 
outcomes and adverse events and this will support the clinician in daily clin-
ical practice. In research settings, remote visits and monitoring could en-
hance recruitment and lower the burden for participants.25 Despite of the 
promising features of the e-diary platform, mobile apps generally do not pro-
vide a one-fits-all solution. We should take notion of the age of future user 
groups, as our results also demonstrated that older patients experienced dif-
ficulties while using the application. Additional training may be required. 
In conclusion, this study shows that a mobile e-diary application can be 
used to remotely monitor patient outcomes and treatment adherence in 
clinical trials with various skin disorders. Therefore, its use for personalized 
monitoring in the outpatient setting should be further explored. Further de-
velopment of e-diaries may improve the collection of real-life patient-report-
ed outcomes and treatment adherence, which may also lead to the improve-
ment of disease outcomes in clinical practice. 
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Introduction 
The human papilloma virus (HPV) is responsible for a spectrum of dermato-
logical and gynaecological lesions. Low-risk HPV types are associated with 
cutaneous warts (CW) and anogenital warts (AGW), whilst high-risk types can 
cause (pre-)malignant lesions of the tissues of the anogenital tract, including 
high-grade squamous intraepithelial lesions of the vulva (vulvar HSIL, for-
merly referred to as usual-type vulvar intraepithelial neoplasma, uVIN).1-4 
Standard treatment for HPV-induced lesions includes surgical excision or 
ablative therapy; however, these can be mutilating and cause physical, psy-
chological and (psycho-)sexual problems.5,6 Overall, current treatment op-
tions for HPV are associated with poor response, high recurrence rates and 
treatment limiting side effects.7,8 Therefore, new treatment options for HPV-
related lesions are under investigation. The response to new dermatological 
therapies is often measured by calipers using traditional linear size assess-
ments. These techniques fail to deliver complete insight into lesion dimen-
sions as they can only assess the diameter and, if applicable, height of a le-
sion, and do not determine surface area or volumetric parameters.9,10 Three-
dimensional (3D) imaging might offer a solution to these limitations. These 
techniques are already widely used in the field of plastic surgery and an-
thropometry to add objective measuring techniques to clinical practice.11-13 
Advantages of 3D imaging include the possibility of offline 3D visualization 
for dimensional quantification and photo documentation over time. A val-
idated 3D imaging system would enable the accurate and highly sensitive 
characterization of detailed skin lesions, and would allow for an adequate 
evaluation of new therapies for HPV-induced lesions. 
Stereophotogrammetry is a technique that obtains two or more images 
from different angles, which can subsequently be reconstructed into a 3D 
image and has been validated for use in scars, basal cell carcinoma, wounds 
and wrinkles.14-20 Currently, this method remains unvalidated for the analy-
sis of HPV-related skin lesions. Before it can be used in the clinical practice, 
3D imaging using stereophotogrammetry requires technical verification for 
the analysis of HPV-related lesions. Therefore, the aim of this study was to 
validate stereophotogrammetric 3D photography for the clinical assessment 
of CW, AGW and vulvar HSIL.
Abstract
Background Quantification of HPV-induced skin lesions is essential for 
the clinical assessment of the course of disease and the response to treat-
ment. However, clinical assessments that measure dimensions of lesions 
using a caliper, do not provide complete insight into 3D lesions and its inter-
rater variability is often poor.
Objective The aim of this study was to validate a stereophotogrammetric 
3D camera system for the quantification of HPV-induced lesions. 
Methods The camera system was validated for accuracy, precision and in-
ter-operator and inter-rater variability. Subsequently, 3D photographs were 
quantified and compared to caliper measurements for clinical validation by 
Bland-Altman modelling, based on data from 80 patients with cutaneous 
warts (CW), 24 with anogenital warts (AGW) patients and 12 with high-grade 
squamous intraepithelial lesions of the vulva (vulvar HSIL) with a total lesion 
count of 220 CW, 74 AGW and 31 vulvar HSIL. 
Results Technical validation showed excellent accuracy (coefficients of 
variation (CV)≤0.68%) and reproducibility (CVs≤2%), a good to excellent agree-
ment between operators (CVs≤8.7%) and a good to excellent agreement be-
tween different raters for all three lesion types (ICCs≥0.86). When compar-
ing 3D with caliper measurements, excellent biases were found for diameter 
of AGW (long diameter 5%), good biases for diameter of AGW (short diameter 
10%) and height of CW (8%) and acceptable biases were found for the diame-
ter of CW (11%) and vulvar HSIL (short diameter 14%, long diameter 16%). An 
unfavorable difference between these methods (bias 25%) was found for the 
assessment of height of AGWs. 
Conclusion Stereophotogrammetric 3D imaging is an accurate and reli-
able method for the clinical visualization and quantification of HPV-induced 
skin lesions.
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photography of the twelve inch ruler and regarding multiple dimensions 
measurement using the wart-like object. Repeated (N=40) 3D images were 
taken of the wart-like phantom object under identical conditions to deter-
mine the precision of repeated measurements. The inter-operator reliabili-
ty of the 3D camera system was determined to validate the use by ten differ-
ent photographers. All obtained 3D images were processed and quantified by 
one trained assessor. 
Patient characteristics
For the clinical validation, i.e. inter rater variability and clinical application, 
of the 3D camera system, HPV-induced skin lesions were photographed dur-
ing three phase 2 clinical trials. These were randomized, double-blind, pla-
cebo-controlled studies to evaluate the efficacy and safety of a topically ap-
plied novel drug on lesions caused by HPV (Supplementary Table 1). All lesions 
were measured by a caliper by a trained physician and trained operators sub-
sequently obtained 3D photographs during all study visits. 
Clinical validation
The images of the CW were processed and quantified by four individual and 
independent raters. Also four individuals scored the AGW lesions. Finally, 3D 
images of vulvar HSIL were independently quantified by two raters. The con-
cordance between different assessors of the 3D images in the imaging software 
(i.e. inter-rater variability) was determined by comparing the quantification 
results of all clinical 3D images of skin lesions taken at the baseline study visit. 
     In addition, the HPV-induced lesions in the three trials were assessed by 
caliper measurements and 3D photography during all visits. The 3D mea-
surements were compared to manual measurements acquired with a digi-
tal Vernier caliper (0-150 mm, Aerospace). The caliper measurements of CW 
and AGW were performed by trained physicians and the vulvar HSIL mea-
surements were performed by a trained physician and a gynaecologist. The 
3D photographs were taken by trained clinical staff. For the CW and AGW, the 
analysis of the 3D photographs was performed after all patients completed 
all visits by one clinical rater. The analysis of the 3D photographs of vulvar 
HSIL was performed after all patients completed all visits by two raters (the 
trained physician and gynaecologist who also performed the caliper mea-
surements) who independently rated all images and had a consensus meet-
ing afterwards. 
Materials and methods 
Device & analysis tools
The LifeViz® Micro (Quantificare, Sophia Antipolis, France) is a compact ste-
reophotogrammetric 3D imaging system. The package includes hardware 
consisting of a 15.1 megapixels, single lens reflex camera (Canon, Tokyo, 
Japan) with a polar flash system and a dual beam pointer used to standardize 
photographing distance at 20 cm. All photographs were taken according to a 
pre-defined standard operating procedure (see Supplemental Fig. 1) in iden-
tical environmental conditions and standardized positioning of the patient 
depending on lesion type (see Supplemental Fig. 2 and 3). All photographs 
were made in the same room with closed blinds and room lights on. The cam-
era distance was set to “micro” to standardize the system-lesion distance to 
20 cm by means of an integrated dual beam pointer. Before taking the pho-
tographs the circumstances were verified using a checklist (Supplementary 
Fig. 4). Photographs were always free hand images and the camera system 
was perpendicularly pointed at the lesion of interest. Baseline photographs 
were used as reference for follow-up photography. Subsequently, the photo-
graph was taken as soon as the dual beam pointers merged onto the lesion of 
interest. Image management, 3D image reconstruction, and 3D analysis were 
performed using DermaPix® software (Quantificare, Cedex, France), which 
is an image management software package providing a database system and 
quantification features. The photographs were uploaded in the software sys-
tem processed as described in Supplemental Fig. 1. The 3D analysis module 
was opened to generate a heat map (indicating height levels). As result ‘dif-
ference’ could be selected in the menu and the contour was loaded to verify 
the correct cement of the manual contour. The lesion dimensions were pro-
vided after loading of the contour. 
Technical validation
For the technical validation of the 3D camera system, a twelve inch ruler 
(Schaedler Quinzel Inc., Parsippany NJ, USA) and a wart-like object manufac-
tured out of lightweight air-drying modeling clay (Hema, the Netherlands) 
were used. 
Accuracy of the stereophotogrammetric 3D imaging system (i.e. ‘3D cam-
era system’) was determined regarding absolute linear measurement by 3D 
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Results 
Technical validation
The technical validation revealed a high accuracy with CVs ranging from 0 to 
0.68% for 3D measurements of units of absolute ruler length (Fig. 1). The pre-
cision of a phantom object analyzed in diameter, height, volume and surface 
area resulted in CVs of 0.69%, 2.0%, 1.5% and 1.1%, respectively.
The inter-operator variability resulted in CVs of 1.9% for longest diame-
ter, 8.7% for height, 2.8% for volume and 2.7% for surface area, indicating that 
analysis of 3D images taken by different trained persons yields similar results. 
For the inter-rater variability, 220 images of different CW, 72 images of dif-
ferent AGW and 31 different images of vulvar HSIL were quantified by the rat-
ers (see Table 1). The ICCs of the inter-rater variability for CW were 0.97, 0.90 
and 0.88 for diameter, height and volume respectively. The inter-rater vari-
ability was similar for common and plantar warts (data not shown). In AGW 
we found an ICC of 0.91 for long diameter, 0.86 for short diameter, 0.90 for 
height and 0.98 for volume. For vulvar HSIL we found an ICC of 0.97 for long 
diameter, 0.94 for short diameter and 0.96 for surface. These data indicate 
that analysis of the 3D images by different raters yielded comparable results.
Clinical validation
Two-hundred-twenty (220) CW of 80 patients were included, of which 114 
common and 106 plantar warts. In total, 1110 measurements of CW were per-
formed, all of which (100%) were eligible for diameter, height and volume 
analysis. Subject characteristics are summarized in Table 1. An example of the 
three lesion types and the 3D reconstruction are shown in Fig 2.
Table 1. The inter-rater variability of 3D photography in HPV-induced skin lesions.
Cutaneous warts (CW) Anogenital warts (AGW) Vulvar HSIL
Dia-
meter
Height Volume Long 
diameter
Short 
diameter
Height Volume Long 
diameter
Short 
diameter
Surface
ICC 0.97 0.90 0.88 0.91 0.86 0.90 0.98 0.97 0.94 0.96
95% 
CI 
0.96, 
0.98
0.88, 
0.92
0.85, 
0.91
0.87, 
0.94
0.80, 
0.91
0.85, 
0.94
0.96, 
0.99
0.93, 
0.99
0.88, 
0.97
0.91, 
0.98
ICC=intra-class correlation coefficient; CI=confidence interval; ICC values of >0.9 were considered as 
excellent and >0.8 as good
The raters who quantified the 3D photographs of the AGW and vulvar HSIL 
also performed the clinical caliper measurements. The quantification pro-
cess was performed after all patients completed all visits. The analysis of 
the 3D data was performed individually and blinded to the assessment of the 
other operators.
The Declaration of Helsinki was the guiding principle for trial execution 
and all subjects gave informed consent before any procedure. The study was 
approved by the Dutch Medical Ethics Committee (“Stichting Beoordeling 
Ethiek Biomedisch Onderzoek”, Assen, the Netherlands). 
The clinical results on the efficacy and safety of the novel drugs investigat-
ed in the phase 2 trials will be published elsewhere.
Statistical analysis
For the technical validation, the accuracy, precision and inter-operator re-
liability of the camera system were expressed by the mean (µ) and standard 
deviation (SD) per measured domain of all images, which were used to deter-
mine the coefficient of variation (CV) in percentage. We pre-specified a CV 
≤5% as excellent, a CV 6-10% as good and a CV 11-20% as acceptable. The intra-
class correlation coefficient (ICC) was established to quantify the variability 
of the 3D image processing and quantification. The ICC was determined in a 
two-way mixed model, with investigators as fixed and the subjects as random 
variable.21 ICC values of 0.7-0.8, 0.8-0.9 and ≥0.9 were considered as of accept-
able, good and excellent agreement, respectively.22,23 
Clinical validation was approached by visualizing the data in Bland-
Altman plots per parameter (where applicable; long diameter, short diame-
ter and height) to represent the agreement between caliper and 3D measure-
ments.24,25 These plots calculate the mean difference between the two mea-
surements (bias, in mm) and the limits of agreement (LoA). We used a linear 
mixed model specified to calculate the bias and limits of agreement based on 
the repeated measurements as described previously.26 Based on the size of 
the lesions, we predefined the biases of ≤5%, 6-10% and 11-20% as percentages 
of the mean baseline caliper measurement as excellent, good and acceptable, 
respectively. These specifications were derived from analytical methods for 
clinical trials and practice.27,28 The comparative analysis between caliper and 
3D measurements was not performed until all 3D data was quantified to avoid 
subjectivity in the manual contours. 
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Figure 3. Forest plot of the bias and Limit of Agreement (LoA) from the Bland-Altman 
analysis for common and plantar warts, anogenital warts and vulvar HSIL. Forest plots 
of the outcomes of the Bland-Altman analysis in CW, AGW and vulvar HSIL.
 
CI= confidence interval, bias is indicated by a square, corresponding LoA are indicated by dots.
Forest plots of the outcomes of Bland-Altman analysis in CW, AGW and vul-
var HSIL are shown in Fig. 3. In CW we found a bias of 0.7mm (11%) with LoA 
of -1.2mm and 2.6mm for diameter. The bias for height was -0.04mm (8%) 
with LoA of -0.5mm and 0.4mm (Fig. 3A). Outcomes for common and plan-
tar warts separately showed no differences (data not shown).
Seventy-two (72) individual AGW of a total of 24 patients were included. 
In total, 341 measurements were performed, all of which (100%) were eligi-
ble for diameter analysis and 270 (79.2%) were eligible for height and volume 
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Figure 1. 3D reconstruction of the twelve inch ruler (A) and wart-like object (B). 
Three-D reconstruction of the twelve inch ruler by the image reconstruction software (A), 
and the wart-like object in a 3D reconstruction with a heat-map showing the height of the 
object which is used for the 3D analysis (B). (see inside back-cover for image in color) 
 
 
 
 
 
 
 
 
 
 
Figure 2. Three-dimensional reconstruction by stereophotogrammetry. A representa-
tive lesion for all three HPV-induced lesions (cutaneous warts, anogenital warts and vulvar 
HSIL) with on the left the 2D photograph, in the middle the 3D reconstruction and on the 
right the heat map showing height differences and the manual contour around the lesion.  
(see inside back-cover for image in color)
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caliper and 3D measurements were acceptable for both the long (14%) and 
short (16%) diameter. However, we did not investigate the errors induced by 
variation of environmental factors such as lighting, distance, variation of the 
plane/positioning in an artificial manner but focused on the standardized 
procedure to readily use it for monitoring HPV-induced lesions in clinical 
practice or after intervention in a clinical trial setting. Of note, calibration of 
the device was not necessary as both the high accuracy (Fig. 1) and the finding 
of a good inter-day precision could be confirmed by the manufacturer. The 
latter was determined by repeatedly (N=27) analysing the geometric parame-
ters over a period of 3 months which showed CVs ranging from 0.65% for di-
ameter to 3.72% for volume (see Supplemental Table 2).
Our technical and clinical validation results correspond to findings in ear-
lier studies utilizing stereophotogrammetry as a method for the qualifica-
tion of dermatological lesions. Robertson and colleagues found an ICC of 0.98 
for volume quantification of hemangiomas in children using the same ste-
reophotogrammetric system as utilized in this study.29 Moreover, a previ-
ous study evaluating pressure ulcer wounds also found excellent inter-oper-
ator variability between operators (ICC=0.99).16 The evaluation of scars with 
stereophotogrammetry demonstrated excellent reliability and validity of the 
technique, although there was only moderate agreement between 3D quan-
tification results and the gold standard (weighing of simulated clay scars).14 
Other studies using stereophotogrammetry for breast dimension assess-
ments reported moderate to good agreement with manual measurements 
due to difficulties in exact determination of the borders.11,12
This study was limited by the absence of a comparison between the caliper 
and 3D measurements for volume and surface area. Indirectly, volume can 
only be calculated by a formula for an ellipse using the caliper measurements 
which often inaccurately reflects the shape of most warts. However, reliably 
including the third dimension of lesions and thus parameters like lesion vol-
ume and height of CW and AGW for detecting drug effects would be advanta-
geous and indisputable for clinicians and drug developers. A similar limita-
tion applies for area calculation of vulvar HSIL. There is no formula that en-
compasses the dimensions of HSIL and on the uneven genital tissue surface 
estimation techniques such as planimetry by tracing cannot be performed.15 
For these reasons, other type of research must be performed to investigate 
the reliability of stereophotogrammetricly acquired volume and surface es-
timations like the artificial system used by Skvara et all.18
measurements. The 71 photographs (20.8%) unsuitable for height and volume 
measurements showed abundant presence of hairs or shadows, which im-
peded the construction of a 3D image. The results of the Bland-Altman anal-
ysis are shown in a forest plot (Fig. 3B). For the measurement of long diam-
eter, we found a bias of 0.2mm (5%) with LoA between -1.5mm and 1.9mm. 
For short diameter we found a bias of 0.3mm (10%) and LoA ranging from 
-0.08mm and 0.7mm. Height bias was calculated as -0.3mm (25%) with LoA 
-0.7mm and 0.2mm. 
Thirty-one (31) vulvar HSIL lesions of 12 patients were included and a total 
of 170 measurements were collected. All were eligible for diameter analysis 
(100%) and 164 (96.5%) were eligible for surface measurements. Photos were 
deemed unsuitable for further analysis when the imaging software was un-
able to compute a correct 3D image because of shadows and hairs disturbing 
the image. The bias values for long and short diameter were 2.3mm (14%) and 
1.8mm (16%), with LoA ranging from -8.9mm and 13.4mm, and -7.1mm and 
10.8mm, respectively (Fig. 3C). 
Discussion 
This validation study is the first to demonstrate that stereophotogrammet-
ric 3D imaging is an accurate and precise method for the characterisation of 
HPV-related lesions and is applicable for the assessment of these lesions in a 
clinical setting. 
The technical validation revealed an excellent accuracy with CVs<0.68%, 
an excellent reproducibility with CVs≤2% and a good to excellent agreement 
with CVs≤8.7% for the inter-operator variability. This indicates that 3D imag-
ing is an exact and highly reproducible method. Three-dimensional photogra-
phy of HPV-related lesions is also reliable for individual raters to assess the ob-
tained photographs, established by good to excellent ICC values (0.86–0.98). 
These results indicate that a single photograph taken in standardized condi-
tions by a trained operator is sufficient for reliable quantification of the lesions. 
       The clinical validation of diameter and height measurements yielded an 
acceptable (11%) and good (8%) bias between caliper and 3D imaging for CW. 
For AGW, we found an excellent (5%) and a good (10%) bias for the long and 
short diameter, respectively, but an unacceptable bias (25%) for the height of 
the AGW. For vulvar HSIL the calculated biases for comparison of the methods 
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offline visualization of the lesions offers an accurate and precise manner to 
follow the lesions during clinical trials. While the focus of our investigation 
was on the clinical application of 3D photography for geometric parameters 
of HPV-induced lesions one might speculate of its potential value for the ob-
jective measurement of lesions with distinct features such as textural chang-
es of the skin in atopic dermatitis or other inflammatory skin conditions.
In conclusion, this study shows that stereophotogrammetry is an ade-
quate tool for accurate and precise evaluation of HPV-induced skin lesions. 
Furthermore, it is applicable as a method for accurate and reproducible photo 
documentation of lesions. Being a portable, hand-held system, the validated 
system offers flexibility and practical advantages over other 3D imaging sys-
tems.13-15 These results need validation in larger cohorts and regarding other 
skin conditions. In addition, future studies should aim at the examination of 
3D photography as a possible biomarker for lesion size assessment and treat-
ment response.  
A limitation of the imaging software was that the contour around the lesions 
had to be drawn manually by the investigator. A system automatically deter-
mining the borders of the lesion would be of great added value but the cur-
rent auto-contour function of the software did not pass the face validity cri-
teria, i.e. already simple assignments would lead to obvious incorrect con-
tour representation (data not shown). However, drawing the manual outline 
and the subsequent automatically calculated size led to reproducible results, 
indicated by a low inter-rater variability (Table 1). 
Limitations of stereophotogrammetry of genital HPV-related lesions con-
cern the plane surface in the vicinity of the lesion of interest, which is a pre-
requisite for the analysis tool during 3D reconstruction. Achieving a plane 
surface is complicated in case of periungual warts, AGW on the labia, fren-
ulum or in the perianal area, or by areas disrupted by the presence of hairs 
projecting over the lesion of interest. The difficulty of accurately picturing 
curved body parts is a feature of 3D imaging systems that has been noted 
previously.13-15 These confounders might have resulted in unreliable mea-
surement of height, surface and volume in this study. It is imperative that 
these data are correctly obtained by the 3D system, as caliper measurements 
only yield rough estimates of these parameters. For instance, we had to omit 
20.8% of the volume and height quantification results of the AGW study due 
to suboptimal image reconstructions. Therefore, we advise potential users 
of stereophotogrammetry to pay extra attention to the removal of obscur-
ing hairs during photography. We discarded images with irregularities in 3D 
reconstructions and erroneous measurements caused by hairs from the data 
that was analyzed for this study. 
Recent studies suggested that following immunotherapy, lesions can first-
ly increase in size before regression, a phenomenon known as pseudopro-
gression. This is caused by influx of immune cells and measured according 
to the iRECIST, a guideline for response criteria for use in immunotherapeu-
tic trials.30,31 Future research should take into account the applicability of 
3D photography as a potential biomarker for response to immune therapy in 
combination with histologic immune infiltration assessments. 
Overall, the added value of 3D imaging over caliper measurements is the 
enhanced accuracy of the measurement. Additional potential applications of 
3D imaging of vulvar HSIL would be collegial or post-hoc consultation, clin-
ical follow-up and training purposes to increase disease awareness among 
clinicians. Furthermore, stereophotogrammetric photo documentation and 
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Introduction
Anogenital warts (AGW) and vulvar high-grade squamous intraepithelial le-
sion (HSIL), formerly referred to as usual type vulvar intraepithelial neopla-
sia (uVIN), are human papillomavirus (HPV)-induced genital lesions.1 AGW is 
the most common sexually transmitted viral disease with a worldwide inci-
dence of 160-289 per 100.000 and is mostly caused by the low-risk HPV type 
6.2-5 Vulvar HSIL is caused by high-risk HPV types, mostly type 16, and has an 
incidence of 1-2 per 100.000.6-8 Vulvar HSIL has a malignant potential of 3% 
when treated, but up to 9% if left untreated.6,9,10 AGW and vulvar HSIL gener-
ally cause similar symptoms such as pruritus and irritation and most patients 
suffer from a high psychological and sexual burden.11-13
The current treatment of AGW and vulvar HSIL consists of ablative/surgi-
cal and medical treatments with efficacy rates of 50-90% and high recurrence 
rates of 15-70%.3,14-20 Surgical treatments are often mutilating and painful 
and medical treatments have notable side effects such as erythema, irrita-
tion, ulceration and pain.12,19,20 Therefore, novel and more effective treat-
ment options with an acceptable side effect profile are needed. 
Omiganan pentahydrochloride, a synthetic analogue of indolicidin, is a small 
antimicrobial peptide from the cathelicidin family that has an important role 
in the first line immune defense of the skin and has antimicrobial proper-
ties against bacteria and fungi.21-24 Omiganan has demonstrated to block 
HPV infection in vitro and has shown immuno-modulatory effects in prima-
ry human immune cell cultures.25 The peptide modifies responses driven 
by cell surface-expressed toll like receptors, in particular type I and type III 
interferon responses which are important for efficient anti-viral activities. 
Omiganan also stimulates the maturation of dendritic cells, reduces the M2-
type (pro-tumor) macrophage profile and enhances the M1-type (anti-tumor) 
macrophage profile.25 Furthermore, omiganan is widely studied in several 
clinical trials in non-viral, dermatological conditions.26-28 The combination 
of its antiviral and immunomodulatory properties makes topical omiganan a 
promising compound for the treatment of HPV-induced diseases. The main 
objective was to investigate the effects of topical omiganan in patients with 
genital dysplasia. The dose rationale was based on preclinical data where an-
ti-HPV effects were observed at dose strength of 25 mg/g.
In this article, we report the results of two randomized controlled trials to 
assess safety and tolerability and to explore pharmacodynamics and clinical 
Abstract 
Aims To assess safety and tolerability and explore pharmacodynamics and 
efficacy of omiganan in external anogenital warts (AGW) and vulvar high-
grade squamous intraepithelial lesions (HSIL).
Methods Two randomized controlled trials in patients with external ano-
genital warts and vulvar HSIL were conducted. Patients received topical omi-
ganan 2.5% or placebo gel once daily for 12 weeks with a follow-up of 12 weeks. 
Safety and tolerability were monitored and pharmacodynamics and clinical 
efficacy of omiganan were assessed by analyzing lesion count, size and viral 
load. Self-reported pain, itch and quality of life were assessed by an electron-
ic diary and questionnaire.
Results Twenty-four AGW and 12 vulvar HSIL patients were enrolled. All 
patients had a high treatment adherence (99%). No serious adverse events 
occurred and all adverse events (N=27) were mild, transient and self-limiting. 
The treatment groups were not different in terms of safety and tolerability, 
lesion count and size and patient-reported outcomes pain, itch and quality 
of life. HPV load significantly reduced after 12 weeks of treatment with omi-
ganan compared to placebo (-96.6%; 95% CI -99.9 to – 7.4%; p=0.045) in AGW 
patients only.
Conclusions Topical omiganan appears to be safe in patients with AGW 
and vulvar HSIL and reduced HPV load after 12 weeks of treatment in AGW 
patients. 
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for 84/85 consecutive days in the AGW and vulvar HSIL trial respectively. The 
amount of study drug depended on the number and size of lesions with a 
maximum of 37.5 mg omiganan per day. Patients returned for a visit at the 
study site after 2, 4, 6 (HSIL only), 8 (AGW only) and 12 weeks and 2 visits were 
planned during the 12-week follow-up period.
Safety and tolerability assessments were performed by monitoring of ad-
verse events (AE), physical examination, ECG and laboratory blood and urine 
tests. AEs were recorded according to the Medical Dictionary for Regulatory 
Activities (MedDRA) version 19. Physical examination and ECG were per-
formed at screening and end of study visit. Blood and urine samples were col-
lected at screening, end of treatment and end of study visit. Pharmacokinetic 
blood samples were taken at the last treatment day of the vulvar HSIL trial 
(pre-dose and 10, 20, 30, 60, 120 and 180 minutes after dosing) and tested by 
validated HPLC/MS/MS with a LoQ of 1.0 ng/mL of omiganan. 
Clinical assessments were performed at each study visit by the same two 
investigators and gynecologist. In the AGW trial, three warts were selected 
for size measurements based on size and reproducibility of repeated mea-
surements; target wart and biopsy wart 1 and 2. Wart size reduction was as-
sessed in longest and shortest diameter and height (mm) was assessed using a 
digital Vernier caliper (0-150 mm, Conrad Electronic Benelux B.V., Oldenzaal, 
the Netherlands). Wart clearance was defined as complete disappearance of 
the wart. In vulvar HSIL patients, clinical response was determined based on 
the RECIST guidelines.29 Complete response was defined as the complete 
disappearance of target lesions. A reduction more than 30% of the sum of 
the longest diameter of the target lesions was classified as partial response. 
Disease progression was defined as the increase of the target lesion and was 
expressed as the sum of longest diameters of >20%, or the development of 
new lesions. 
Swabs were collected at each study visit by rubbing the surface of the tar-
get lesion for 5 consecutive times with a pre-wetted cotton-tipped stick. The 
cotton stick was placed in 1 mL of saline solution and stored at -40 degrees 
Celsius. Swabs for PCR analyses were taken before omiganan was applied. 
All swabs were analyzed batch-wise at the end of study to limit variability. 
Nucleic acid isolation was performed on the MagNA Pure 96 system, using 
the DNA and Viral NA Large Volume Kit. The input for the nucleic extraction 
procedure was 350µL of swab, 100µL of 0.9% NaCl and an added volume of 
50µL of 10 times concentrated phosphate buffered saline. Nucleic acids were 
efficacy of topically applied omiganan once daily in patients with AGW and 
vulvar HSIL. These studies were the first to test an antimicrobial peptide for 
its antiviral properties in HPV-induced diseases. The results of both stud-
ies are combined to establish a profile incorporating different HPV–induced 
diseases. 
Materials and methods
Study design, patients and randomization
Two randomized, double-blind, placebo-controlled, parallel-group, phase 2 
trials in patients with AGW and vulvar HSIL were performed at the Centre 
for Human Drug Research (CHDR), Leiden, The Netherlands. Patients of ≥18 
years with biopsy-proven HPV positive AGW or histologically proven vulvar 
HSIL were included. Eligible patients had at least 3 external AGW or a vul-
var HSIL of 20mm in diameter or 120mm2 surface. Exclusion criteria were 
active treatment of the lesions within 28 days prior to enrollment, immu-
nosuppression, pregnancy, breast-feeding or inability to use effective con-
traception during the treatment period and at least 90 days afterwards. All 
participants gave written informed consent before randomization. The stud-
ies were approved prior to any clinical activities by the independent Dutch 
Medical Ethics Committee (Stichting BEBO, Assen, The Netherlands). 
Patients were randomly assigned to topical omiganan or placebo gel in a 
2:1 ratio by a computer-generated list prepared by an independent statisti-
cian. In the vulvar HSIL trial subject numbers were sequentially allocated by 
chronological enrollment. In the AGW trial male patients were numbered se-
quentially from 1 upwards and female patients from 24 downwards in order 
of inclusion and were randomized in blocks of 3, to enable the inclusion of 
at least 3 patients of each gender per treatment. Patients, study personnel 
and investigators were blinded for allocated treatment throughout the study. 
Patients of the vulvar HSIL trial could be enrolled in an open label study part B 
with an additional 12 weeks treatment and 12 weeks follow-up, if there were 
no safety or tolerability issues in the double-blind study part and no suspect-
ed progression. 
Study procedures
The participants were instructed by the study physician or nurse practitio-
ner to apply the study drug once daily at approximately the same clock time 
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filled out during the visit days and consisted of questions from a validated 
vulvar HSIL questionnaire (supplemental data).33 All answers were scored and 
higher scores indicated a higher level of burden of disease. Scores were added 
up, providing mean total quality of life (QoL) scores. Higher QoL scores indi-
cated a lower QoL. Treatment adherence, the actual administrations divid-
ed by the expected administrations, was monitored by the e-diary to register 
daily dose administration and to remind patients; in case patients did not fill 
in the e-diary, they were contacted and asked whether they applied the drug. 
The expression of HPV was corrected using the expression of the housekeep-
ing genes ACTB and RPL11.
Statistical analysis
Due to the exploratory nature of the trials and the first-in-indication setting, 
sample size was determined empirically. Safety analyses were conducted 
in the pre-defined intention-to-treat (ITT) population, which comprised of 
all enrolled patients who received at least one dose of study treatment. The 
pharmacodynamics and efficacy analyses were conducted in the per proto-
col population, which consisted of the ITT population with at least one post-
baseline assessment and no major protocol deviation. All efficacy and phar-
macodynamic endpoints were analyzed using a mixed model analysis of co-
variance (ANCOVA) using treatment, time and treatment by time as fixed fac-
tors, patient as random factor and the baseline value as covariate with SAS 
9.4 for Windows (SAS institute Inc., Cary, NC, USA). A two-sided Fisher’s exact 
and a two-sided Wilcoxon exact rank test were used to analyze wart clear-
ance. Graphs were made using GraphPad Prism (version 6.05 for Windows, 
GraphPad Software, La Jolla, California, USA). All statistical tests were two-
tailed with α-level of 0.05.
Results
Patient characteristics
Between November 2015 and July 2017, eligibility for participation in the AGW 
trial and vulvar HSIL trial was assessed in 31 and 15 individuals respectively 
(Figure 1). Twenty-four patients with AGW and 12 patients with HSIL were ran-
domized. Data of one AGW patient was excluded due to a major protocol de-
viation (study procedure incompliance) and one AGW patient was excluded 
from analysis of the follow-up period due to use of concomitant treatment 
eluted in a volume of 50µL of elution buffer. All DNA isolates were tested for 
PCR inhibition by a real-time PCR detecting a plasmid spiked in the PCR mix. 
An increase in cycle threshold value of the plasmid spike in clinical samples 
would indicate PCR inhibition. When PCR inhibition was found the DNA from 
the swab was diluted 10x and retested to confirm that PCR inhibition was no 
longer present. The 10x diluted sample was used in the HPV qPCR and viral 
load was corrected for the 10x dilution. The base line swab DNA isolates were 
tested on HPV genotype using the SPF10-LiPA25 version 1 (Labo Bio-medical 
Products B.V., Rijswijk, The Netherlands). The viral load of HPV 6 and HPV 11 in 
case of AGW and HPV16 in case of vulvar HSIL was determined by three sepa-
rate qPCRs in swabs of lesions that were positive for the respective HPV type 
as determined on the baseline sample. The target of the quantitative PCRs 
was the E6 open reading frame and an input volume of 5µL of isolated nucle-
ic acid was used per qPCR. Determining viral loads was done by comparing 
the cycle threshold value of the clinical samples with the cycle threshold val-
ues of a standard curve specific for each HPV type and analyzed in each qPCR 
run. Quantitative PCRs were validated and limit of detection and lower limit 
of quantification values for HPV6, HPV11 and HPV16 were 14/100, 12/100 and 
8/32 copies/PCR respectively.
One 3mm biopsy was obtained at screening (biopsy wart 1), week 12 (bi-
opsy wart 2) and week 24 (target wart) in case of AGW and two 3mm biopsies 
were obtained at screening, week 6, week 12 and week 24 of the same lesion 
in case of vulvar HSIL. The AGW biopsies were directly cut into two equal 
pieces and were further evaluated by the LUMC department of pathology. 
One piece/biopsy was assessed according to conventional pathological stan-
dards by the same gynecologic pathologist after hematoxylin and eosin (H&E) 
staining.30,31 HPV-typing was performed in the screening biopsy using INNO-
LiPA HPV genotyping Extra II (INNO-LiPA; Fujirebio Europe, Ghent, Belgium). 
From the other piece/biopsy RNA was isolated by means of the Nucleospin 
Kit RNA XS (Macherey-Nagel, Düren, Germany), cDNA was synthesized and 
thereafter the expression of HPV6 (AGW) or HPV16 (vulvar HSIL) was deter-
mined using real-time PCR with a primer targeted for E6.
Patient-reported outcomes were determined by a study-specific smart-
phone application (e-diary) and a paper questionnaire.32 In the e-diary appli-
cation, the symptoms pain and itch were assessed by a numeric rating scale 
(NRS) once daily during the treatment period on a scale from 0 to 100 (0: 
no pain/pruritus and 100: worst pain/pruritus). The paper questionnaire was 
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Table 1. Baseline characteristics of patients.  
 
Characteristics
AGW trial Vulvar HSIL trial
Omiganan Placebo Total Omiganan Placebo Total
Gender – N (%)
Female
Male
6 (37.5)
10 (62.5)
3 (37.5)
5 (62.5)
9 (37.5)
15 (62.5)
8 (100)
-
4 (100)
-
12 (100)
-
Age in years 
– median (range)
30 (20-46) 40 (23-64) 33 (20-64) 55 (35-71) 46 (29-51) 52 (29-71)
Number of 
lesions 
– median (range)
8 (4-62) 18 (10-43) 11 (4-62) 2 (1-3) 4.5 (2-6) 2.5 (1-6)
Lesion size in mm 
– median (range)
Long diameter
Short diameter
Height
4.3 (2.4-7.8)
3.0 (1.4-4.8)
1.3 (0.2-3.0)
4.7 (4.2-7.3)
3.8 (2.1-5.2)
1.3 (0.5-2.1)
4.4 (2.4-7.8)
3.3 (1.4-5.2)
1.3 (0.2-3.0)
16 (10-40)
10 (5-20)
-
10 (5-30)
7 (4-30)
-
16 (5-40)
10 (4-30)
-
Disease duration 
In years – median 
(range)
1.7 
(0.3-10.5)
1.5 
(0.2-5)
1.6 
(0.2-10.5)
5.0 
(0.1-25.8)
5.5 
(0.9-8.5)
5.3 
(0.1-25.8)
HPV type biopsy - N
HPV6
HPV11
HPV16
HPV18
HPV33
HPV44
HPV51
HPVXa
13b
-
-
-
-
1
1b
2
7
1
-
-
-
-
-
-
20b
1
-
-
-
1
1b
2
-
-
6c
1c
2c
-
-
1
-
-
4
-
-
-
-
-
-
-
10c
1c
2c
-
-
1
Previous treatment 
– N (%)
11 (69) 8 (100) 19 (79) 7 (88) 4 (100) 11 (92)
Cryotherapy 5 2 7 - - -
Surgical excision 3 1 4 3 1 4
Podofyllotoxine 4 7 11 - - -
Imiquimod 4 3 7 6 3 9
Sinecatechins 1 0 1 - - -
Trichloroacetic acid 1 0 1 - - -
Laser - - - 2 1 3
Vaccination trial - - - 1 0 1
Smoking
No
1-15/day
15+/day
10
5
1
4
3
1
14
8
2
2
4
2
0
3
1
2
7
3
Symptoms
no
itch
pain
itch and pain
13
2
1
0
4
4
0
0
17
6
1
0
5
0
0
3
3
0
0
1
8
0
0
4
a: HPVX= unidentifiable HPV type.  / b: One patient had a co-infection (HPV6 and HPV51) / c: Two patients 
had a co-infection (HPV16 and 18, HPV16 and 33)
for AGW (after consultancy with research physician). Seven subjects were en-
rolled in part B of the vulvar HSIL trial. Baseline characteristics of all patients 
are described in Table 1. The evaluation of HPV type showed that HPV6 (83.3%) 
and HPV16 (83.3%) were the most frequently occurring types in AGW and vul-
var HSIL patients respectively. 
Figure 1. Integrated flowchart of the AGW and vulvar HSIL trial. In the AGW trials 31 
subjects were screened of whom 24 (77%) were enrolled. Of the 24 remaining subjects, 16 
were randomly assigned to treatment with omiganan and 8 to placebo. One subject in the 
omiganan group discontinued the intervention due to personal reasons, the end of study 
visit was performed prematurely. One subject in the placebo group was excluded from 
analysis in the follow-up period because of use of concomitant medication for AGW. In 
the vulvar HSIL trials 15 subjects were screened of whom 12 (80%) were enrolled. Of the 
12 remaining subjects 8 were randomly assigned to treatment with omiganan and 4 to 
placebo. All subjects completed the study.
	  
	  
	  
	  
	  
	  
Assessed for eligibility: 
AGW: n=31  
HSIL: n=15 
Excluded 
♦	  	  	  Not meeting inclusion criteria  
AGW: n=7 
  HSIL: n=3 
Analysed   
AGW: n=15 
− Excluded from analysis due to non-reliable 
data and incompliance (n=1) 
HSIL: n=8	  
Lost to follow-up (n=0) 
Discontinued intervention: 
      AGW n=1 (due to incompliance for   
      personal reasons) 
      HSIL n=0 
Allocated to omiganan 2.5% 
♦	  Received allocated intervention 
AGW n=16 
HSIL n=8	  
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to placebo 
♦	  Received allocated intervention 
AGW n=8 
HSIL n=4	  
	  
Analysed  
AGW: n=8 
−	  Excluded from follow-up analysis due to 
receiving another treatment for genital warts 
after consulting research physician (n=1) 
HSIL: n=4	  
	  
Allocation	  
Analysis	  
Follow-­‐Up	  
Randomized: 
AGW: n=24 
HSIL: n=12 
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group was detected compared to the placebo group (-30.3%; 95% CI -51.8 to – 
0.7%; p=0.054). Biopsies showed no difference in histology between the two 
groups of both trials, although in AGW patients treated with omiganan three 
biopsies were not taken because of clearance of the lesion while the in the 
AGW placebo group one biopsy was missing due to clearance of the lesion. 
Figure 2. Photography assessments of lesions over time. Photography of a patient with 
angenital warts (a) and vulvar HSIL (b), both patients were treated with omiganan. Pre-dose 
(day 0) the lesions are clearly visible. Upon treatment, the genital warts clearly resolve (a) 
and the vulvar HSIL remained the same (c). The patient of picture 2a had total clearance of 
the genital warts at EOS, but a post-inflammatory hypopigmentation has occurred at the 
lesion site. Day 0 is before start of treatment, day 84 is at the end of treatment (EOT) and 
day 168 is at the end of study (EOS). (see back-inside cover for image in color) 
Anogenital wart (agw)
 day 0 (pre-dose) day 84 (eot) day 168 (eos) 
 
Vulvar hsil
 day 0 (pre-dose) day 84 (eot) day 168 (eos)
Safety, tolerability and pharmacokinetics
There were no serious adverse events and no study discontinuations or with-
drawals due to adverse events. An overview of all treatment-emergent AEs 
is provided in Table 2. All AEs (N=34) were mild, transient and self-limiting. 
There were no systemic treatment-emergent adverse events. Almost all ad-
ministration site symptoms (11/12) were in the omiganan group and probably 
related to the treatment. One AGW patient did not apply the investigational 
product for two weeks after having consulted the research team, due to ad-
verse events (pruritus, erythema and irritation at application site). Hereafter, 
the investigational product was re-introduced and was applied every other 
day until the end of treatment without re-emergence of the side-effects. 
Table 2. Treatment-emergent adverse events.
System  
organ class / 
preferred  
term
AGW Vulvar HSIL
Omiganan (N=16) Placebo (N=8) Omiganan (N=8) Placebo (N=4)
Events Subjects Events Subjects Events Subjects Events Subjects
N N (%) N N (%) N N (%) N N (%)
Any event 8 7 (43.8) 1 1 (12.5) 3 3 (37.5) 0 0 (0)
Administration site conditions
Burning 
sensation
1 1(6.3) 1 1(12.5) 2 2 (25) - -
Erythema 1 1(6.3) - - - - - -
Induration 1 1(6.3) - - - - - -
Pruritus 4 3(18.8) - - 1 1 (12.5) - -
Skin hypopig-
mentation 
1 1(6.3) - - - - - -
Clinical efficacy
Clinical impressions of patients with genital warts and vulvar HSIL treat-
ed with omiganan are shown in Figure 2. The clinical efficacy of omiga-
nan in genital warts and HSIL is summarized in Table 3. There was no dif-
ference in clearance of both AGW and vulvar HSIL between omiganan and 
placebo and no differences were found in study part B of the vulvar HSIL 
trial. A trend towards a decrease in the mean height of AGW in the omiganan 
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HPV clearance
The median viral load in LN copies/µL as measured with swabs at baseline 
was 4.6 (range -6.9 – 12.1) for AGW and 5.7 (range 1.9 – 9.5) for vulvar HSIL. In 
the AGW trial, the amount of viral DNA in the omiganan group showed a sta-
tistical significant decrease during the study period compared with the pla-
cebo group (-96.6%; 95% CI -99.9 to – 7.4%; p=0.045), Figure 3a. There were 
no differences in viral load in vulvar HSIL swabs between omiganan and pla-
cebo (Figure 3b). Remarkably, in the swabs 4 hours after treatment with omi-
ganan a decrease was seen compared to the swabs pre-dose (-73.1%; 95% CI 
-94.3 – 25.9%; p=0.08). The relative expression of HPV measured in the biop-
sies showed no differences between omiganan and placebo in patients with 
AGW and HSIL (supplemental figures). 
Figure 3. Viral load shown as change from baseline (CFB). A qPCR was performed to 
determine the HPV load in the swabs of both trials. Analysis of viral load in swabs was 
performed using a mixed model with treatment, time and treatment by time as fixed 
factors and subject as random factor. All statistical tests were two-tailed with an α-level 
of 0.05. A statistical significant difference was found when comparing the HPV load of 
AGW patients treated with omiganan compared to placebo (-96.6%; 95% CI -99.9 to – 7.4%; 
p=0.045) (a). No statistical difference was found when comparing the HPV load of vulvar 
HSIL patients treated with omiganan compared to placebo (b).
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exposure (twice daily dosing) would have been more efficacious. Skin swabs 
from viral lesions do not represent a homogeneous sample matrix like blood. 
However, HPV viral load determination has previously been shown to be a re-
liable marker in prior studies.36 To mitigate the risk of high variability in viral 
load measurements in the skin swabs a standard protocol was used by trained 
clinicians dedicated to the project. 
We showed remarkable differences in omiganan treatment on viral load 
in patients with low-risk HPV type (AGW) versus patients with high-risk HPV 
type induced lesions (vulvar HSIL). In AGW patients, we noted a significant de-
crease in low-risk HPV load after omiganan treatment, opposed to no differ-
ence in high-risk HPV load in vulvar HSIL patients. While HPV6 and HPV16 are 
all in the Alpha genus of the phylogenetic tree of Papillomaviridae which is 
based on the DNA sequence of the L1 open reading frame, both HPV types ex-
hibit different biological properties. HPV6 is mostly implicated in benign le-
sions whereas HPV16 is the main cause of HPV-induced cancers. In this study 
we investigated the effect of omiganan on two distinct lesion types. AGW 
is a benign lesion, whereas vulvar HSIL is a premalignant lesion, which can 
progress to vulvar cancer. Also, analyses of complete genome sequences have 
found that HPV16 is more diverse with four variant lineages, compared with 
two variant lineages for HPV6.38,39 These differences along with their onco-
genic properties may lead to the hypothesis that omiganan can interfere with 
the low-risk HPV type 6 and 11, but may not be effective for high-risk HPV type 
16. A possible explanation might be that high-risk HPV types cause integra-
tion of the viral DNA into the human genome and overexpression of the E6 
and E7 oncoproteins, which are not amenable to omiganan treatment.
Limitations of our study include the small sample sizes in the AGW and 
HSIL trials, the lack of dose ranging in both trials and the abscence of mea-
surements of omiganan in the lesions, which makes it hard to draw conclu-
sions about the efficacy of the drug. One patient was excluded from the ef-
ficacy analyses because of non-adherence reasons, however non-adherence 
was related to personal reasons, and not to treatment-related reasons or ad-
verse events. Biopsies in AGW patients were taken from different lesions and 
no biopsies were taken if a lesion was cleared. It should therefore be noted 
that the AGW trial comprised of subjects with treatment-resistant AGW that 
had been present for a longer time. It cannot be excluded that omiganan 
might have shown higher efficacy rates in subjects with recently developed, 
treatment-naive AGW. Strengths of our study are the well-controlled study 
Patient-reported outcomes
For vulvar HSIL, both pain and itch showed a high inter-patient variability 
and no statistical significant differences were seen between the treatment 
groups (p=0.81 and p=0.66, in pain and itch respectively). For AGW, most pa-
tients did not experience any pain and there was a minimal inter-patient vari-
ability for both symptoms. There was no difference in total QoL score be-
tween the treatment groups in both vulvar HSIL and AGW patients (p=0.16 
and p=0.94 respectively), see supplemental figures. The treatment adher-
ence was 99% in both trials. 
Discussion
This study demonstrates that despite the lack of clinical efficacy, omiganan 
reduced the viral load of AGW and demonstrated a favorable safety profile in 
AGW and HSIL patients. The distribution of the low and high-risk HPV types 
in AGW and vulvar HSIL patients was similar to the distribution found in lit-
erature.5,6 This is the first study to show the use of skin swabs as a biomarker 
in the genital area related to antiviral treatment monitoring. We previously 
showed that skin swabs can be used for antiviral treatment monitoring for 
cutaneous warts.35,36 These studies showed a good correlation of the HPV 
load between swabs and gold standard biopsies. Performing swabs instead 
of multiple biopsies has major advantages: a lower patient burden because 
of its non-invasive nature, the ability to assess the viral load of a single lesion 
over time and its lack of curative effect, i.e. by removing the lesion or by in-
ducing an immune response. Previous research has shown that the viral load 
as assessed in cervical swabs is inversely related to HPV16 clearance and may 
therefore predict whether HPV infections become persistent or not.37 A sig-
nificant reduction in HPV load was found in swabs of treated AGW patients, 
which could suggest a suppression of the viral infection by omiganan. In the 
in vitro experiments we found that omiganan blocks HPV infection and has 
immune-modulatory effects, the reduction of the viral load in AGW patients 
support these in vitro results.25 In the vulvar HSIL trial we tested the viral 
load 4 hours after administration of the drug and we observed a decrease 
of the viral load in the omiganan group. It is tempting to hypothesize that 
omiganan reduced the viral load shortly after application and that extended 
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Introduction
Cutaneous warts, or verrucae, are a common benign skin condition with 
an estimated prevalence of 3-13% in the general population in the Western 
world.1 Most people are affected by cutaneous warts, either plantar warts 
(located on foot soles), or common warts (mostly located on hands or dorsal 
feet), at some point in their life (Kilkenny and Marks, 1996).1-4 
Although cutaneous warts are benign and usually resolve spontaneous-
ly, they affect both physical and psychosocial discomfort.6 Many patients 
use a variety of wart-removing products.5-8 Efficacy rates of common treat-
ments are approximately 39% for cryotherapy, 24% for salicylic acid and 46% 
for monochloroacetic acid, whereas spontaneous regression rates are around 
16%.7,9-11 As current treatments such as cryotherapy and monochloroacetic 
acid often have side effects (e.g., pain, erythema and burning sensation) and 
low efficacy rates, there is a need for therapies with a greater efficacy and 
minimal side effects.12-15 
Cutaneous warts are caused by the human papillomavirus (HPV). The great 
majority (>80%) of verrucae in the general population is related to HPV1, 2, 27 
and 57.16-21
It is well known that papillomaviruses are dependent of the milieu of the in-
fected host cell for proliferation.22,23 More specifically, it has been shown 
that DNA viruses, such as HPV rely on potassium influx (K+) for replication.24 
The cardiac glycoside digoxin and loop diuretic furosemide both inhibit de 
K+ influx by interacting with the cell membrane ion co-transporters Na+/
K+- ATPase and Na+- K+- 2Cl-. These two compounds may therefore be valu-
able for the treatment of HPV-induced diseases, such as cutaneous warts. In 
2006, an in vitro study found that the inhibitory effect on DNA replication 
was most potent when digoxin and furosemide were combined. This new 
approach with two well-know, established drugs, described as Ionic Contra-
Viral Therapy (ICVT), is suggested to be most effective via local application.25
A previous phase 1/2 open-label study recently demonstrated safety and 
efficacy of ICVT in a group of 12 healthy subjects with common warts.26 The 
aim of the current proof-of-concept study was to assess clinical efficacy, safe-
ty and tolerability of ICVT in adults with cutaneous warts in a single-cen-
ter, randomised, double-blind, placebo-controlled phase 2A trial. The second-
ary objective was to gain insight into the underlying working mechanism of 
ICVT.
Abstract
Background Topical Ionic Contra-Viral Therapy (ICVT) comprised of di-
goxin and furosemide inhibits the potassium influx on which DNA viruses 
rely for replication. Therefore, ICVT was hypothesised to be a potential novel 
treatment for cutaneous warts. 
Objectives To assess clinical efficacy, safety and tolerability of ICVT in 
adults with cutaneous warts. Secondary objective was to gain insight into 
underlying working mechanism of ICVT.
Methods Treatment with ICVT was assessed for efficacy, safety and tol-
erability in a single- centre, randomised, double-blind, placebo-controlled 
phase 2A trial. Eighty adult subjects with at least 2 cutaneous warts (plantar 
or common) were randomised to one of 4 treatments: digoxin + furosemide 
(0.125%), digoxin (0.125%), furosemide (0.125%) or placebo and administered 
the gel once daily for 42 consecutive days. Pre-defined statistical analysis was 
performed with a mixed model analysis of covariance. 
Results Wart size and HPV load reduction was achieved in all active treat-
ment groups. A statistically significant reduction in wart diameter of all treat-
ed warts was shown in the digoxin + furosemide treatment group versus pla-
cebo (-3.0mm; 95% CI -4.9 to -1.1mm; p=0.002). There was a statistically sig-
nificant reduction in HPV load of all treated warts in the digoxin + furosemide 
group compared to placebo (-94%; 95% CI -100 to -19; p=0.03). With wart size 
reduction, histologically and immunohistochemically defined viral charac-
teristics disappeared from partial and total responding warts. 
Conclusions This study demonstrates proof-of-concept for the efficacy 
of topical ICVT in adults with cutaneous warts. 
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Figure 1. Study design. The treatment phase entailed 42 days with study visits at day 0, 
14, 28 and 42. The follow-up phase lasted for 56 days with study visits at day 70 and 98. 
The treatment period was 42 days with patient visits at day 0, 14, 28 and 42. At all visits 
the following assessments were performed of all warts: wart size measurement, wart 
morphology, photography, swab. At day 98, a biopsy was performed of the primary and 
untreated wart.  
 
 
 
 
 
 
 
 
 
 
 
EOT = End of treatment; EOS = End of study.
Study procedures 
The primary objective was to investigate clinical efficacy of ICVT by analyz-
ing wart size reduction and viral load in primary warts in the four treatment 
groups. Wart size reduction was assessed in diameter and height (mm) by a 
digital vernier caliper (0-150 mm, Aerospace). Wart clearance (defined as 100% 
reduction) was assessed by a dermatological sub-investigator. Viral load was 
measured with use of skin swabs.26 In addition, 2 biopsies of the primary 
wart and the untreated reference wart were taken at the end of study (EOS). 
The HSL-PCR/MPG assay (LMNX kit HSL-PCR, Labo Bio-medical Products) en-
ables the simultaneous identification of 23 warts-associated HPV types from 
the alpha (HPV2, 3, 7, 10, 27, 28, 29, 40, 43, 57, 77, 91 and 94), gamma (HPV4, 
48, 50, 60, 65, 88 and 95), mu (HPV1 and 63) and nu-genus (HPV41).16,27 Viral 
load was determined for all swabs and biopsy samples of primary warts that 
were positive for HPV1, 2, 27 or 57 by qPCR. 
The secondary objective was to gain insight into the underlying working 
mechanism of ICVT. Therefore, wart morphology was assessed to confirm or 
reject the hypothesis that wart size reduction can be predicted by morpho-
logical aspects of all warts in this study. Standardized photographs of the pri-
mary wart were taken and wart morphology was assessed using the CWARTS 
diagnostic tool.28,29 Complete responders were defined as showing a reduc-
tion of 100% in size, partial responders a reduction between 25% and 100% in 
Visit 
Swab 
Photography 
Morphology 
Biopsy 
Day 
Baseline 
↓ 
EOT 
↓ 
EOS 
↓ 
0 7 14 21 28 35 42 49 56 63 70 77 84 91 98 
↑ ↑ ↑ ↑ ↑ ↑ 
+ + + + + + 
+ + + + + + 
+ + + + + + 
+ 
Materials and methods
Study design, participants and randomization
A randomised, double-blind, placebo-controlled, parallel-group, single-cen-
ter phase 2 trial was conducted. The Declaration of Helsinki was the guid-
ing principle for trial execution, and the study was approved by the inde-
pendent Medical Ethics Committee “Medisch Ethische Toetsingscommissie 
van de Stichting Beoordeling Ethiek Biomedisch Onderzoek” (Assen, the 
Netherlands) prior to any procedure. Patients were included if they were 
(other than the skin condition) healthy, 18 years or older, and had at least 2 
(non-subungual, non-genital and non-facial) common or plantar warts with 
a diameter of minimal 3 mm, diagnosed by a dermatologist and after giving 
written informed consent. A maximum of 5 warts per subtype were followed 
during the study. Patients were excluded if they had been exposed to wart-
removing products within 30-60 days prior to enrolment, depending on the 
treatment. For women of childbearing age, effective contraception was re-
quired during study execution and at least 90 days afterwards. The study con-
sisted of a screening phase (weeks -4 to 0), a treatment phase (weeks 0 to 6) 
and a follow-up phase (weeks 6 to 14), as shown in Figure 1. 
Subjects were randomised 1:1:1:1 in blocks of four to receive one of the 
four treatment regimens: digoxin + furosemide (0.125%, w/w) digoxin (0.125% 
w/w), furosemide (0.125% w/w) or vehicle, which served as placebo with an 
identical appearance. Randomization was predefined and performed in SAS 
by an independent statistician and subject numbers were sequentially allo-
cated by chronological enrollment. Subjects, study personnel and investiga-
tors were blinded for allocated treatment throughout the study. At baseline, 
all warts were numbered by a blinded independent clinical staff member; for 
common warts starting from 1 with a maximum of 5 and for plantar warts 
starting from 6 with a maximum of 10. Wart number 1 or 6 was selected as 
untreated wart (N=80) and the other warts were selected as treated warts. 
Of the treated warts 1 wart per subject was selected as primary wart (biop-
sy wart, N=80) using a randomly generated number in SAS drawn by an inde-
pendent statistician. 
Study site
The study was conducted from December 2014 to August 2015 at the Center 
for Human Drug Research, Leiden, The Netherlands. 
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Results
Patients 
Hundred-and-fourteen (114) otherwise healthy subjects with cutaneous warts 
were screened of whom 81 (71%) were enrolled in the trial; 1 withdrew before 
randomization (see Fig. 1 and Fig. 2). All subjects (N=80) completed the study 
and there were no treatment discontinuations or early withdrawals. Baseline 
demographic and disease characteristics were comparable in all four treat-
ment groups (see Table 1). 
Figure 2. Flowchart of the study of all subjects and warts. One-hundred and fourteen 
(114) otherwise healthy subjects with cutaneous warts were screened of whom 81 (71%) 
were enrolled in the trial; 1 withdrew before randomization. Of the 80 remaining subjects, 
20 were randomly assigned to one of four treatment groups: digoxin + furosemide, 
digoxin, furosemide or placebo, all to be locally applicated in gels. All subjects (N=80) 
completed the study and there were no treatment discontinuations or early withdrawals.
Assessed for 
eligibility (n=114)
 
Excluded  (n= 34) 
  Not meeting inclusion criteria (n=33) 
  Declined to participate (n=1) 
Analysed  (n=20)1
Warts (n=47) 
•Common (n=21) 
•Plantar (n=26) 
Allocated to digoxin + 
furosemide (n=20)  
Allocated to 
furosemide (n=20)  
Allocation 
Analysis 
Randomized 
(n=80)  
Enrollment 
Allocated to 
vehicle (n=20)  
Allocated to 
digoxin (n=20)  
Analysed  (n=20) 
Warts (n=59) 
•Common (n=32) 
•Plantar (n=27) 
Analysed  (n=20) 
Warts (n=53) 
•Common (n=30) 
•Plantar (n=23) 
Analysed  (n=20) 
Warts (n=61) 
•Common (n=31) 
•Plantar (n=30) 
1: In the digoxin+furosemide group the pharmacodynamics measurements of the primary wart of 1 subject 
were excluded. 
size and non-responders less than 25% reduction of wart size at EOS compared 
to baseline. A subset of 20 warts of subjects was chosen based on response 
(complete, partial or non-responders) for a histopathology and immunohis-
tochemistry (IHC) analysis, in order to confirm or reject the hypothesis that 
wart size reduction can be predicted by viral characteristics, Ki-67 (cell pro-
liferation) and HPV E4 (marker of a productive infection) patterns. Viral char-
acteristics (histopathology), Ki-67 (clone MIB-1; Dako/Agilent Technologies) 
and HPV E4 patterns (SILgrade-E4-1 kit containing XR-E4-1 monoclonal an-
tibody, Labo Bio-medical Products) were assesses by two blinded reviewers 
and without prior knowledge of responder or HPV status. All analyses were 
independently performed by two reviewers except for the Ki67 analysis that 
was discussed during microscopy. 
Safety and tolerability were monitored by tracking of adverse events (AEs), 
performing physical examination, measuring vital signs, 12-lead electrocar-
diograms, and laboratory tests (i.e. hematology, chemistry, coagulation, and 
urinalysis) and by systemic therapeutic drug monitoring for systemic expo-
sure of digoxin at multiple time points throughout the study. Treatment ad-
herence was measured by monitoring all daily dose administrations via a val-
idated mobile e-diary application. After application of the gel, trial subjects 
took a photo of all warts with use of the mobile e-diary.
Statistics
A sample size of 20 patients per treatment group was estimated based on the 
analysis of primary warts to provide >90% power to demonstrate superiori-
ty of digoxin and/or furosemide over placebo with a difference in means of 
31.6mm3, assuming that the common standard deviation is 30, using a two 
group t-test with a 0.05 two-sided significance level.26 All efficacy/pharma-
codynamic endpoints were analyzed in the intention to treat population, 
with a mixed model using treatment, time and treatment by time as fixed 
factors and subject as random factor. The pre-defined primary analyses to 
investigate clinical efficacy of ICVT were performed for primary warts only. 
For pre-defined secondary analyses to gain insight into underlying working 
mechanism of ICVT was based on all treated warts, and within subject was 
added as random factor to the model. All statistical tests were two-tailed with 
α-level of 0.05. A two-sided Fisher’s exact and a two-sided Wilcoxon exact 
rank test were used to analyze wart clearance. Correlation between qPCR in 
swab samples and biopsies was investigated using a linear regression model 
with subject as random factor. 
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Treatment adherence
Seventy-eight (78) of the 80 subjects (97.5%) applied the gel once daily for 
more than 35 consecutive days and only sporadically subjects did not comply 
to the daily treatment regimen. Most subjects applied a dose within the range 
of 5-30 mg per wart per day. However, the mean amount of study medication 
applied per wart per day was highly variable (range: 2.9-118 mg). 
Wart size reduction
Figure 3A shows a reduction in primary wart diameter measured by caliper 
from baseline to end of study (EOS) in all active treatment groups. A statisti-
cally significant effect (p<0.05) was found in the digoxin + furosemide group 
versus placebo (-2.5mm; 95% CI -4.9 to -0.1; p=0.04), while the two other 
treatment groups (digoxin vs placebo and furosemide vs placebo) showed no 
statistically significant effects (-1.5mm; 95% CI -3.9 to 0.9; p=0.21, and -1.1mm; 
95% CI -3.4 to 1.3; p=0.38, respectively). Changes in diameter were most pro-
nounced after end of treatment (EOT), as shown in Figure 3A. In the analy-
sis of all treated warts (N=139) a statistically significant wart size reduction 
measured by caliper was observed between each active treatment group and 
placebo (digoxin + furosemide versus placebo; -3.0mm; 95% CI -4.9 to -1.1; 
p=0.002, digoxin vs placebo -1.9mm; 95% CI -3.7 to -0.2; p=0.03, furosemide 
versus placebo -2.1mm; 95% CI -3.8 to -0.4; p=0.01) as is shown in Figure 3B. 
Wart clearance
At the EOS, primary warts (N=80) showed comparable clearance rates in all 
active treatment groups, i.e. 3/19 (16%) in the digoxin + furosemide group, 
3/20 (15%) in the digoxin group and 3/20 (15%) in the furosemide group. In 
contrast, no clearance was observed in the placebo treated group (N=20). A 
two-sided Fisher’s exact test revealed no statistically significant differences 
when active treatment groups were compared to the placebo group. Table 2 
shows comparable clearance rates in all treated warts in the 3 active treat-
ment groups. Supplemental data (Table A) shows the rates of clearance ob-
served in treated common warts (24-27%) and treated plantar warts (8-15%) at 
EOS. When including all warts with a reduction of ≥90% diameter, the high-
est response rate was seen in common warts treated with digoxin + furose-
mide (N=5) at EOS with a response rate of 45%. In Figure 3C an example of a 
photography assessment of a treated wart in the digoxin + furosemide group 
is shown.
Table 1. Patient characteristics. 
 
Characteristics Digoxin+ 
Furosemide
(N= 20)1
Digoxin  
(N= 20)
Furosemide  
(N= 20)
Placebo  
(N= 20)
Total
(N=80)
Mean age in years (SD) 23.8 (±7.9) 30 (±13.5) 23.5 (±5.5) 26.1 (±12.7) 25.8 (±10.6)
Sex – no. (%)
Male
Female 
6 (30)
14 (70)
11 (55)
9 (45)
7 (35)
13 (65)
7 (35)
13 (65)
31 (39)
49 (61)
Mean time since diagnosis 
in years
5.3 7.6 6.9 4.9 6.2
Total amount of warts – no. 47 53 61 59 220
Mean number of warts  
per subject – no.
2.4 2.7 3.1 3 2.8
Subjects with common warts 
– no. (%)
9 (45) 10 (50) 10 (50) 10 (50) 39 (49)
Amount of common  
warts – no. (%)
21 (45) 30 (57) 31 (51) 32 (54) 114 (52)
Treated common  
warts – no. (%)
12 (57) 19 (63) 21 (68) 21 (66) 73 
Subjects with plantar  
warts – no. (%)
11 (55) 9 (45) 10 (50) 9 (45) 39 (49)
Amount of plantar  
warts – no. (%)
26 (55) 23 (43) 30 (49) 27 (46) 106
Treated plantar warts – no. (%) 15 (58) 13 (57) 20 (67) 17 (63) 65
Subjects with both common  
and plantar warts – no(%)
0 (0) 1 (5) 0 (0) 1 (5) 2 (3)
Size of warts – mean 
diameter (mm)
6.6 6.4 6.4 6.5 6.5
Size of primary wart – mean  
diameter (mm) 
6.02 6.56 6.47 6.45 6.38
HPV type primary wart
HPV1
HPV2
HPV27
HPV57
Other2
0
5
6
6
2
0
4
10
2
4
0
3
10
3
4
0
6
3
6
5
0
18
29
17
15
Any previous treatment – 
no. (%)
16 (80) 17 (85) 14 (70) 15 (75) 62 (78)
Cryotherapy – no. (%) 12 (60) 16 (80) 12 (60) 14 (70) 54 (68)
Cimetidine – no. (%) 0 (0) 1 (5) 0 (0) 0 (0) 1 (1)
Electrocoagulation – no. (%) 0 (0) 1 (5) 0 (0) 0 (0) 1 (1)
Fluorouracil – no. (%) 0 (0) 1 (5) 0 (0) 0 (0) 1 (1)
Monochloor, Salicylic and  
trichloric acid – no. (%)
7 (35) 8 (40) 9 (45) 6 (30) 30 (38)
Surgery – no. (%) 1 (5) 2 (10) 0 (0) 0 (0) 3 (4)
1: In the digoxin + furosemide group the pharmacodynamics measurements of the primary wart of one 
subject were excluded / 2: Other = HPV3, HPV4and HPV10.
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Viral load
At baseline, 200 of the 219 (91%) warts (one missing sample) were positive 
for DNA from the 23 tested HPV types. HPV27 was most prevalent (38%) fol-
lowed by HPV57 (26%) and HPV2 (24%). Of the 219 warts, 186 (85%) were posi-
tive for one of the HPV types for which viral load testing was available (i.e., 
HPV1, 2, 27, 57). No statistical differences were found when comparing the 
HPV load of primary warts (N=79) in swabs from baseline to EOS in the treat-
ment groups with the placebo group (digoxin + furosemide -8%; 95% CI -96 to 
1952; p=0.96, digoxin -6.3%; 95% CI -96 to 2086; p=0.97 and furosemide 80%; 
95% CI -92 to 3966; p=0.71), as is shown in Figure 4A. However, when compar-
ing the viral load change of HPV from baseline to EOS in the swabs of all treat-
ed warts (N=139), there was a statistically significant reduction of viral load, 
only in the digoxin + furosemide group versus placebo (-94%; 95% CI -100 to 
-19; p=0.03) (see Fig. 4B). In biopsies, no statistically significant differences in 
HPV load were seen in the treatment groups versus placebo. There was a sig-
nificant correlation (p<0.0001) between viral load in swabs and biopsies at the 
EOS (Fig. 4C). We observed a significant correlation (p=0.001) between wart 
size reduction and reduction in HPV load (data not shown).
Response analyses 
In case of wart elevation, a significantly decreased wart diameter was ob-
served at EOS after 6 weeks of treatment with the combination treatment 
digoxin + furosemide compared to placebo (-5.2 mm; 95% CI -8.6 to -1.8; 
p=0.003). The morphologic aspects callus and smooth/rough wart did not 
show any difference in prediction of wart size reduction (see Table 3). 
In Table 4, a summary of the responder analysis is given, based on 9 responder 
warts (i.e., 3 complete responders, 6 partial responders) and 11 non-respond-
ers. The individual data is available in Supplemental Data: Table B. H&E stain-
ing showed changes characteristic of viral infection in biopsies from non-re-
sponder warts in contrast to the biopsies from complete and partial respond-
er warts. In the IHC of the non-responders the Ki-67 was positive suprabasal 
(scattering) in all biopsies, comparing to a basal Ki-67 pattern in all complete 
responders, i.e. 100% and 5 out of 6 partial responders, i.e. 83.3% (Table 4). 
Staining of the HPV E4 protein, indicative of a productive HPV infection, was 
positive in all non-responders and related to a high HPV load in EOS biopsies 
and swabs (see Table 4). Concordantly, in all complete and partial responders 
Figure 3. Change from baseline (CFB) least squares mean (LSM) of diameter of primary 
warts (a) and all treated warts (b) and photography assessments of a common wart of sub-
ject #6 (digoxin+furosemide) (c). (a) Analysis of the primary endpoint for the intention-to-
treat population (N=79) was performed using a mixed model with treatment, time and treat-
ment by time as fixed factors and subject as random factor. All statistical tests were two-tailed 
with α-level of 0.05. Results showed a statistically significant reduction of wart size in the 
digoxin+furosemide group compared to placebo (-2.5mm; 95% CI -4.9 to -0.1; p=0.04). Single 
treatment groups (digoxin vs placebo and furosemide versus placebo) showed no statistically 
significant effects (-1.5mm; 95% CI -3.9 to 0.9; p=0.21, and -1.1mm; 95% CI -3.4 to 1.3; p=0.38, re-
spectively). Changes in diameter were most pronounced after EOT, as shown in Figure 3A. (b) 
In the analysis of all treated warts (N=139) a statistically significant wart size reduction was ob-
served between each active treatment group and placebo (digoxin+furosemide versus place-
bo; -3.0mm; 95% CI -4.9 to -1.1; p=0.002, digoxin vs placebo -1.9mm; 95% CI -3.7 to -0.2; p=0.03, 
furosemide versus placebo -2.1mm; 95% CI -3.8 to -0.4; p=0.01). (c) A photography assessment 
of a treated wart in the digoxin+furosemide group. (see inside back-cover for image c in color)
EOT= end of treatment; EOS= end of study. 
Table 2. Clearance of all warts per subject at end of study. 
Characteristics Digoxin+ 
Furosemide
(N= 191)
Digoxin  
(N= 20)
Furosemide  
(N= 20)
Placebo  
(N= 20)
Wart clearance2 (p-value treatment vs placebo)
All warts3 – no. (%)
At least 1 wart, but not all warts4 – no. (%)
No clearance – no. (%)
0.11
2 (11)
1 (5)
16 (84)
0.23
2 (10)
1 (5)
17 (85)
0.11
2 (10)
2 (10)
16 (80)
-0 (0)
0 (0)
20 (100)
1: In the digoxin+furosemide group the pharmacodynamics measurements of the primary wart of one subject 
were excluded / 2: Clearance defined as 100% reduction / 3: All warts of the subject were cleared /  
4: At least one wart, but not all warts, of the subject was cleared 
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Safety
No treatment related study discontinuations occurred. The AE profile was 
comparable in all treatment groups. Nasopharyngitis, headache and influ-
enza-like illness were the most frequently occurring mild and self-limit-
ing treatment-emergent AEs (see Supplemental Data: Table C). No clinical-
ly relevant changes in vital signs and laboratory assessments were observed. 
Digoxin values measured for therapeutic drug monitoring were all below the 
Limit of Quantification (LoQ, 300pg/mL). 
Table 3. Wart morphology in relation with wart size in digoxin + furosemide 
treatment group. 
Wart diameter (mm)
Difference1 95% CI2 P-value
Callus: Present (N=42) / Absent (N=37) -1.71 -5.12 to 1.70 0.3203
Capillary thrombosis: Present (N=45) / Absent (N=34) -2.51 -6.15 to 1.13 0.1730
Level Elevation: (N=44) / Flat (N=35) -5.21 -8.60 to -1.82 0.0031
Aspect  Smooth: (N=17) / Rough (N=62) -1.86 -5.85 to 2.13 0.3357
1: Difference of the mean diameter as measured by caliper / 2: CI=confidence interval
Table 4. Response analyses per responder group. HE + IHC staining biopsies and viral 
load in biopsies and swabs. 
Responder Swab baseline Biopsy EOS Swab EOS
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Complete 
(N=3)
TND1 (1/3)
HPV3 (1/3)
HPV57 (1/3)
5.62 0/3 E4 (0/3)
Ki-67 (3/3)3  
HPV2 (1/3)
2.95 HPV (0/3) 05 
Partial 
(N=6)
HPV2 (2/6)
HPV27 (2/6)
HPV57 (2/6)
4.7 0/6 E4 (0/6) 
Ki-67 (5/6)3 (1/6)4 
HPV2 (1/6)
HPV27 (1/6)
HPV57 (3/6)
3.85 HPV2 (2/6) 
HPV57 (2/6)
1.15,6 
Non (N=11) HPV2 (3/11)
HPV27 (4/11)
HPV57 (4/11)
4.9 11/11 E4 (11/11)
Ki-67 (11/11)4
HPV2 (4/11)
HPV27 (4/11)
HPV57 (3/11)
8.8 HPV27 (4/11)
HPV2 (4/11)
HPV57 (3/11)
4.3
1: Target not detected (TND) for the 23 HPV types included in the broad spectrum genotyping assay / 2: 
Samples of subject without HPV DNA detected and HPV3 at baseline are not further tested for viral load and 
therefore not included in the mean / 3: Basal staining, restricted to the basal layer / 4: Scattered staining
5: Samples not tested are considered as zero / 6: Samples where the target is not detected are considered as 
zero / EOS = end of study
the E4 staining was negative. The mean viral load in biopsies and swabs at 
EOS was lower in the complete and partial responders compared to the non-
responders. In Figure 5 examples of the H&E staining of a classical verruca 
vulgaris and plana are illustrated, showing typical viral characteristics.
Figure 4. HPV viral load in swabs depicted as percentage change from baseline (CFB) 
least squares mean (LSM) of primary wart (a) and all treated warts (b) and correlation 
of HPV viral load in swabs versus biopsy at end of study (c). (a) Analysis of primary 
warts (N=79) was performed using a mixed model with treatment, time and treatment 
by time as fixed factors and subject as random factor. All statistical tests were two-tailed 
with α-level of 0.05. No statistical differences were found when comparing the HPV load 
of primary warts (N=79) in swabs from baseline to EOS in the treatment groups with the 
placebo group (digoxin + furosemide -8%; 95% CI -96 to 1952; p=0.96, digoxin -6.3%; 95% CI 
-96 to 2086; p=0.97 and furosemide 80%; 95% CI -92 to 3966; p=0.71). (b) Viral load change 
of HPV from baseline to EOS in the swabs of all treated warts (N=139) was a statistically 
significant only in the digoxin + furosemide group versus placebo (-94%; 95% CI -100 to -19; 
p=0.03). (c) Correlation between qPCR in swab samples and biopsies was investigated using 
a linear regression model with subject as random factor. There was a significant correlation 
(p<0.0001) between viral load in swabs and biopsies at the EOS. The line depicts the linear 
correlation: Viral load swab = -4.8+0.56*viral load biopsy. 
EOT= end of treatment; EOS= end of study.
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Efficacy rates therapies 
Efficacy rates of the most common used treatments are estimated to be 
around 39% for cryotherapy, 24% for salicylic acid and 46% for monochlo-
roacetic acid. In the current study, ICVT efficacy rates were estimated to be 
comparable to the efficacy rates reported in literature, i.e., around 45% in 
common warts. However, it should be noted that the current trial consisted 
of subjects with treatment resistant warts that had been present for a long 
time (mean time of onset 4.9 – 7.6 years in the treatment groups). It can there-
fore be anticipated that ICVT might have shown higher efficacy rates in sub-
jects with more recently developed warts.
Delayed response to ICVT
Interestingly, wart size reduction in diameter and clearance both occurred 
predominantly after EOT. One explanation might be that ICVT interferes 
with the HPV life cycle 22, which firstly results in a reduction of HPV load and 
thereafter reduction in wart size. It looks like the disappearance of signs of 
HPV infection precedes the actual vanishing of the wart. This is supported by 
the fact that E4 staining, indicative of a productive infection, in the response 
analysis showed that partially cleared warts were in viral regression, show-
ing less E4 signals and less papillary patterns. Another explanation could be 
reservoir forming of ICVT in the hyperkeratotic layer that slowly releases 
the drug into the lesion and thereby resulting in a delayed and prolonged re-
sponse. Studies with a longer follow-up period and without the biopsy inter-
vention at EOS have to be considered to better understand effectiveness of 
ICVT in both mono active and dual active form. 
Systemic effects of ICVT
Warts without application of the research gel in the active treatment groups 
reduced in size, in contrast to the placebo group, which suggests that this 
reduction was not due to spontaneous regression. The observed clearance 
might be explained by distant effects of the gel, i.e., increased activation of 
the immune system might have led to activity in untreated distant warts. 
Cardiac glycosides such as digoxin are known to influence the immune re-
sponse at multiple levels 31, thus digoxin in the formulation might be held 
responsible for this. This distant clearance concept is also known from 
Discussion
This study demonstrates clear and statistically significant pharmacodynamic 
effects of topical ICVT on common and plantar warts with a favorable safety pro-
file. Both lesion reduction and clearance rates indicate pharmacological activ-
ity and demonstrate proof-of-concept of ICVT in adults with cutaneous warts. 
Effects of ICVT was slightly more pronounced in patients with common 
warts. This is in accordance with previous studies wherein evident differ-
ences between response to treatment of common and plantar warts were re-
ported.7, 30 The increased treatment resistance of plantar warts was previ-
ously described and seems to be mainly due to callus formation resulting in 
a decrease in cutaneous permeability of a drug.28
Figure 5. Histological representative cases of classical cutaneous viral warts. (a) 
Verruca vulgaris H&E low power view (50x) with architectural characteristic inturning 
of the elongated rete ridges, epidermal hyperplasia, papillomatosis, hypergranulosis, 
hyperkeratosis and columns of parakeratosis. (b) Verruca vulgaris H&E, detail view (200x): 
note koilocytes (arrowhead) and coarse granula (arrows) mostly in top layers (stratum 
granulosum). (c) H&E low power view (50x) of verruca plana with epidermal hyperplasia, 
hypergranulosis, hyperkeratosis, koilocytes in middle and upper layers. (d) verruca plana 
H&E, detail view (100x) note the absence of papillomatosis, parakeratosis and coarse 
granula. (see inside cover for image in color) 
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conclude that there is a clear correlation between the histopathological di-
agnoses, presence of E4 and Ki-67 pattern and HPV load.
Morphologic aspects of the warts could be useful to predict wart size re-
duction, based on the results of the current study. In clinical practice this 
might be helpful to have insight into the morphological characteristics when 
deciding about the most effective and personalised treatment. 
Safety
Current options for therapy all have high rates of side effects including pain 
and irritation at the application site, blistering and scarring.7,13 Such local ir-
ritations were not observed in the current trial.
In conclusion, our findings clearly show proof-of-concept of topical ICVT 
for cutaneous warts with the most pronounced effects of digoxin and furo-
semide when combined in a formulation for common warts. A treatment pe-
riod of 42 days was well tolerated and led to significant wart size reduction 
and occasionally clearance. As hypothesised, wart size reduction was relat-
ed to HPV load reduction measured by qPCR in swab, proving that this swab 
method can be a valuable, non-invasive disease biomarker for drug develop-
ment in cutaneous warts. As clinical outcomes, such as clearance of lesion 
sites often require long-term treatment and follow-up, we indicate the found 
efficacy in the current study as proof-of-concept of ICVT in cutaneous warts. 
Further investigations to evaluate total clearance and recurrence rates after 
a longer treatment and follow-up period are recommended. 
another topical compound, imiquimod. Psoriasis patients treated with im-
iquimod can locally develop total body psoriasis exacerbations during treat-
ment based on distant skin immune system activation by imiquimod.32-34
HPV distribution and load by swabs suitable  
biomarkers for cutaneous warts 
The distribution of HPV types in warts in this study was similar to the distri-
bution found in common and plantar warts in literature 21 except for HPV1. 
This can logically been explained by the study sample, containing adults, 
whereas HPV1 infections are more prevalent among children with warts pres-
ent for less than 6 months.21 
Skin swabs have been frequently used to determine HPV status of subjects 
in a research setting, but not yet in relation to antiviral treatment monitor-
ing.35,36 Wart swabs are ideal for sampling in order to determine viral load, 
as the golden standard HPV status determination (biopsy) has several disad-
vantages such as the burden for the patient, the practical difficulty of taking 
multiple biopsies from a single small lesion, as well as the potential study bias 
caused by the curative effect of taking a biopsy.37 The current study showed 
that viral load determined in swabs correlated with viral load determined 
from biopsies of the same wart. These data confirm the correlation previous-
ly reported by van der Kolk et al, but now in a larger sample set warranting 
the continued use of this marker in clinical studies.26 
Response analyses
Outcomes from microscopical and IHC analyses of the biopsies at EOS corre-
spond with those from the viral load analysis: biopsies and swabs of the com-
plete and partial responders have a lower viral load or are HPV negative which 
corresponds with loss of changes in the epithelium characteristic of viral in-
fection, absence of E4 staining and a basal Ki-67 staining, whereas the non-
responders had high viral loads in swab and biopsies. H&E staining of the bi-
opsies showed signs of changes related to viral infection, E4 staining and a 
scattered Ki-67 staining. The HPV E4 protein disrupts the keratin filamen-
tous network and inhibits formation of the cornified envelope. Detection of 
E4 is indicative of a productive viral infection.22,38 Ki-67 is a biomarker for 
cell proliferation and in normal epithelium the Ki-67 signals are restricted 
to the basal layer. By reactive change, the Ki-67 positivity is also observed in 
the other layers of the epithelium (scattered staining).39 From this, we can 
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of the literature and mechanism. Br J Dermatol. 
2011;164(3):670-2.
33 Chakrabarty AK, Mraz S, Geisse JK, Anderson NJ. 
Aphthous ulcers associated with imiquimod and the 
treatment of actinic cheilitis. J Am Acad Dermatol. 
2005;52(2 Suppl 1):35-7.
34 Maronas-Jimenez L, Morales-Raya C, Burillo-Martinez 
S, Velasco-Tamariz V, Rodriguez-Peralto JL, Vanaclocha-
Sebastian F. Aphthous vulvar ulcers: a paradoxal adverse 
effect at distance of topical imiquimod? Eur J Obstet 
Gynecol Reprod Biol. 2016;198:156-7.
35 Hazard K, Karlsson A, Andersson K, Ekberg H, Dillner J, 
Forslund O. Cutaneous human papillomaviruses persist 
on healthy skin. J Invest Dermatol. 2007;127(1):116-9.
36 Weissenborn SJ, De Koning MN, Wieland U, Quint WG, 
Pfister HJ. Intrafamilial transmission and family-specific 
spectra of cutaneous betapapillomaviruses. J Virol. 
2009;83(2):811-6.
37 Petry KU, Horn J, Luyten A, Mikolajczyk RT. Punch 
biopsies shorten time to clearance of high-risk human 
papillomavirus infections of the uterine cervix. BMC 
Cancer. 2018;18(1):318.
38 Doorbar J. The E4 protein; structure, function and 
patterns of expression. Virology. 2013;445(1-2):80-98.
39 Chow LT, Broker TR. Human papillomavirus infections: 
warts or cancer? Cold Spring Harb Perspect Biol. 
2013;5(7).  
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Introduction
Anogenital warts (AGW) are caused by the human papilloma virus (HPV), 
mostly type 6 and represent the most common sexually transmitted viral 
disorder.1 AGW cause pruritus, irritation or pain and most patients experi-
ence substantial psychological burden.2 Current treatment options are as-
sociated with low efficacy rates, serious side effects and high recurrence 
rates.3,4 Therefore the development of novel effective treatments with ac-
ceptable side effects is crucial for patients with AGW. Ionic contra-viral ther-
apy (ICVT), comprised of digoxin and furosemide, inhibits the cellular K+ in-
flux.5 Recently, a phase 2 randomized-controlled trial showed a reduction in 
size and viral load of HPV-induced cutaneous warts after 6 weeks of treat-
ment with topical ICVT.6,7 Based on these findings we hypothesized that 
ICVT could show clinical activity in another HPV-induced disease, i.e. AGW. 
The objectives of this study were to evaluate safety and tolerability and to ex-
plore pharmacodynamics and clinical efficacy of ICVT in patients with AGW.
Materials and Methods
Study design
A randomized, double-blind, placebo-controlled, phase 2 trial was conduct-
ed from October 2017 until July 2018 at the Centre for Human Drug Research 
(CHDR), Leiden, The Netherlands. The study was approved by the Dutch in-
dependent Medical Ethics Committee of the Foundation BEBO (Assen, the 
Netherlands) prior to any procedure. Patients ≥18 years were considered eli-
gible for the study if they had a minimum of 3 external AGW and were other-
wise healthy. Patients were prohibited to use active treatment for AGW with-
in 28 days prior to enrolment until the end of study. The patients were ran-
domly assigned by a computer-generated list prepared by an independent 
statistician to either a fixed dose of a topical gel of ICVT, containing digoxin 
and furosemide (0.125%, w/w), or placebo in a 3:1 ratio. The study drug was ap-
plied once daily for 42 consecutive days with a follow-up period of 12 weeks. 
Patients, study personnel and investigators were blinded for allocated treat-
ment throughout the study. Patients could be enrolled in an open label ex-
tension study, with 8 weeks treatment and 12 weeks follow-up, if no safety or 
tolerability issues occurred in the double-blind study part. 
Abstract 
Background Anogenital warts (AGW) are caused by low-risk HPV types 
and represent the most common sexually transmitted viral disease. Current 
therapies for AGW have notable side effects and high recurrence rates. DNA 
viruses such as HPV rely on cellular K+ influx. Ionic contra-viral therapy (ICVT) 
comprised of digoxin and furosemide inhibits the K+ influx and is therefore 
a potential new treatment for AGW.
Objectives A randomized, controlled trial was performed to assess safety 
and tolerability and explore pharmacodynamics and clinical efficacy of ICVT 
in patients with AGW.
Methods Twenty-four patients with at least 3 external AGW were ran-
domized to either ICVT or placebo (ratio 3:1) and administered the gel once 
daily for 42 consecutive days. To assess safety and tolerability, laboratory 
safety testing was performed and adverse events, vital signs and ECGs were 
monitored. Clinical efficacy was assessed by lesion count and dimensions, 
measurement of viral load, HPV expression and histology. Patient-reported 
outcomes and quality of life (QoL) were assessed with use of an e-diary and 
paper questionnaires. 
Results ICVT was well tolerated as there were no clinically relevant safety 
findings and no serious adverse events. All adverse events (N=17) were of mild 
severity and self-limiting. No between-group differences in lesion count, di-
mensions, viral load, patient-reported outcomes and QoL were observed 
after treatment. 
Conclusion ICVT is safe to be administered in patients with AGW but 
shows no pharmacodynamic activity or clinical efficacy after 6 weeks of 
treatment.
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and treatment by time as fixed factors, patient as random factor and the base-
line value as covariate with SAS 9.4 for Windows (SAS institute Inc., Cary, 
NC, USA). A two-sided Fisher’s exact and a two-sided Wilcoxon exact rank 
test were used to analyze wart clearance. Graphs were made using GraphPad 
Prism (version 6.05 for Windows, GraphPad Software, La Jolla, California, 
USA). All statistical tests were two-tailed with α-level of 0.05.
Figure 1. Flow diagram of the study. Thirty-two subjects were screened of whom 24 (75%) 
were enrolled. Of the included subjects, 18 were randomly assigned to treatment with 
ICVT and 6 to placebo. All subjects completed the study. 
Results
Twenty-four patients were enrolled and all subjects completed the trial (Fig. 
1). Patient characteristics are shown in Table 1. The most frequently present 
HPV-type in baseline biopsy specimens was HPV6 (92%) and most patients 
(79%) had undergone one or more previous treatments. No serious AEs oc-
curred and there were no study discontinuations. All AEs (N=17) were of mild 
severity and self-limiting. The most frequently reported AE was a burning 
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Follow-Up 
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Study procedures
Safety and tolerability were monitored by tracking of adverse events (AEs), 
physical examination, vital signs, ECG and laboratory blood and urine tests. 
Systemic exposure of digoxin was measured during the treatment period 
at week 3 and 6. All warts were counted and the diameter and height (mm) 
of three selected warts, i.e. target wart (TW), biopsy wart 1 (BW1) and biop-
sy wart 2 (BW2), were measured using a digital calliper (HBM Machines B.V., 
Moordrecht, the Netherlands). Swabs were taken at each study visit and 
were analyzed in a single batch at the end of study. The HPV genotype was 
identified in baseline swabs using SPF10-LiPA25 version 1 (Labo Bio-medical 
Products B.V., Rijswijk, The Netherlands).6-8 Viral load of HPV6 and HPV11 
was determined by qPCR in all swabs. Biopsies were taken at baseline (BW1), 
end of treatment (BW2) and end of study (TW) and were cut in two equal 
pieces. One piece of the biopsy was assessed according to histopathologi-
cal analyses by the LUMC department of pathology.9,10 HPV genotyping was 
performed of BW1 using INNO-LiPA HPV genotyping Extra II (INNO-LiPA; 
Fujirebio Europe, Ghent, Belgium). From the other piece, the expression of 
the HPV6 E6 gene was determined using real-time quantitative reverse tran-
scriptase PCR. Patient-reported outcomes were determined with use of an 
e-diary during the treatment period and quality of life (QoL) by paper ques-
tionnaires at each study visit.11 The questionnaire was based on adapted ques-
tions from a vulvar HSIL questionnaire.12 Treatment adherence, the actual 
administrations divided by the expected administrations, was monitored by 
the e-diary to register daily dose administration and to remind patients; in 
case patients did not fill in the e-diary, they were contacted and asked wheth-
er they applied the drug.
Statistics 
Due to the exploratory nature of the trial the sample size was determined 
empirically. Safety analyses were conducted in the pre-defined intention-to-
treat (ITT) population, comprising all enrolled patients who received at least 
one dose of study treatment. Pharmacodynamic and clinical efficacy analy-
ses were conducted in the per protocol population, which consisted of the 
ITT population with at least one post-baseline assessment and no major pro-
tocol deviation. All efficacy and pharmacodynamic endpoints were analyzed 
with a mixed model analysis of covariance (ANCOVA) using treatment, time 
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to 11.2; p=0.03), because of a decrease in the mean itch score in the placebo 
group. There was no difference in total score of the QoL between the treat-
ment groups (+22.4; 95% CI -70.1 to 114.9; p=0.62). Treatment adherence was 
99%. Twelve subjects were enrolled in the open label extension study, which 
showed no differences upon treatment.
Discussion
This study was performed to evaluate safety and tolerability and to ex-
plore pharmacodynamics and clinical efficacy of ICVT in patients with AGW. 
ICVT has demonstrated a favorable safety profile in patients with AGW, and 
that no pharmacological nor clinical activity occurred upon the once daily 
Table 2. Clinical efficacy of ICVT compared to placebo. 
Assessment
AGW
Pre-dose EOT1 EOS2 P-value
Lesion count – mean (SD) ICVT 15 (12.7) 15 (12.2) 9.9 (8.1) 0.89
Placebo 12.8 (5.9) 13.3 (7.4) 6.6 (4.5)
Long diameter in mm – 
mean (SD)
ICVT 5.1 (2.7) 5.5 (3.0) 4.1 (3.5) 0.49
Placebo 6.4 (1.8) 6.5 (1.7) 5.9 (3.8)
Short diameter in mm – 
mean (SD)
ICVT 3.1 (1.8) 3.5 (1.9) 2.6 (2.1) 0.84
Placebo 3.9 (1.4) 3.7 (1.4) 3.4 (2.3)
Height in mm – mean 
(SD)
ICVT 1.8 (2.2) 1.7 (2.6) 1.6 (2.9) 0.43
Placebo 1.6 (0.6) 1.8 (1.3) 1.1 (0.7)
Viral load swab in LN 
copies/µL – mean (SD)
ICVT 2.1 (5.1) 2.4 (4.8) 1.8 (4.4) 0.68
Placebo 2.7 (4.9) 3.3 (2.1) -0.3 (5.0)
Relative HPV6 E6 
expression biopsy – 
mean (SD)
ICVT 0.41 (0.05) 0.34 (0.12) 0.68 (0.08) 0.27
Placebo 0.90 (0.06) 0.74 (0.06) 0.08 (0.001)
Histology ICVT AGW 11/18
Other 7/183
Normal 0/18
AGW 8/18
Other 
10/183 
Normal 0/18
AGW 13/18
Other 2/183 
Normal 0/18
No biopsy 3/184
-
Placebo AGW 6/6
Other 0/6
Normal 0/6
AGW 3/6
Other 3/63 
Normal 0/6
AGW 5/6
Other 1/63 
Normal 0/6
1:  After 6 weeks of treatment / 2: After 12 weeks of follow-up / 3: Other= seborrheic verruca, fibro epithelial 
polyp, hyperkeratotic papilloma or reactive changes. Although, all biopsies taken pre-dose were HPV 
positive. / 4: Three patients refused the biopsy at the end of study / ICVT: ionic contra-viral therapy, EOT: 
end of treatment, EOS: end of study
sensation at the application site directly after application of the gel, which 
was reported by 6 (33%) patients in the ICVT group and 3 (50%) patients in 
the placebo group. All other AEs were considered as unrelated to treatment. 
Safety laboratory testing, vital signs and electrocardiograms showed no dif-
ferences between the treatment groups. There was no difference upon treat-
ment in number, dimensions, viral load, HPV6 expression and histology be-
tween the ICVT and placebo group (Table 2). There was no statistical signifi-
cant difference in pain scores between both treatment groups (+1.3; 95% CI 
-1.3 to 4.0; p=0.30). When comparing the itch scores, there was a statistically 
significant difference between the ICVT and placebo group (+5.9; 95% CI 0.7
 
Table 1. Patient characteristics at baseline.  
Characteristics ICVT ( N=18) Placebo (N=6) Total (N=24)
Gender
Female
Male
4 (22%)
14 (78%)
1 (17%)
5 (83%)
5 (21%)
19 (79%)
Age in years - median (range) 27.5 (21-44) 33 (22-67) 28 (21-67)
Number of lesions – median (range) 10 (4-51) 14 (6-19) 10 (4-51)
Target wart size in mm – median (range)
Long diameter
Short diameter
Height
4.6 (2.7-14.2)
2.8 (1.3-9.3)
1.3 (0.4-9.7)
6.1 (3.8-8.5)
3.9 (2.1-5.5)
1.6 (0.8-2.3)
4.8 (2.7-14.2)
2.8 (1.3-9.3)
1.4 (0.4-9.7)
Disease duration in years – median (range) 3 (0.1-11.8) 5.4 (0.4-7.7) 3.8 (0.1-11.8)
HPV genotype biopsy – N (%)
HPV6
HPV44
HPV73
17 (94)
1 (6)
0
5 (83)
1 (17)
11 (17)
22 (92)
2 (4)
11 (8) 
Previous treatment 
No – N (%) 3 (17) 2 (33) 5 (21)
Yes – N (%) 15 (83) 4 (67) 19 (79)
Cryotherapy 8 2 10
Surgical2 7 2 9
Medical3 13 4 17
Smoking
No
1-15/day
15+/ day
10
5
3
3
3
0
13
8
3
Symptoms4
no
yes
10
8
4
2
14
10
1: One subject had a co-infection of HPV6 and HPV73 / 2: Surgical excision and laser / 3: Podofyllotoxine, 
imiquimod, sinetachins, 5-FU / 4: Pain and/or pruritus / ICVT: ionic contra-viral therapy
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administration of ICVT for 42 consecutive days. As expected, HPV6 was the 
most frequently present (92%) HPV-type.13,14 In our previous trial with cu-
taneous wart patients ICVT showed clear reduction in wart size and viral 
load after 6 weeks of treatment.15 As cutaneous warts are hyperkeratotic le-
sions often associated with callus growth, while AGW are commonly more 
smooth lesions, it is reasonable to think that the uptake and delivery of the 
drug in AGW is not responsible for the lack of efficacy. Two explanations can 
now be given for the lack of pharmacological and clinical activity of ICVT in 
our study. One explanation might be the difference in biological properties 
of the HPV type that causes AGW (HPV6) and cutaneous warts (HPV2, HPV27 
and HPV57). Both are members of the Alpha-papillomavirus group.16 In plan-
tar warts, the HPV genotype has been found to influence natural history and 
treatment response.17 Clinical practice shows that not all treatments effec-
tive in cutaneous warts are also effective in AGW, and vice versa. For example, 
imiquimod is registered for the use in AGW and shows an efficacy of 27-54%.18 
Several small and non-controlled trials performed to investigate the efficacy 
of imiquimod in cutaneous warts showed limited evidence for its efficacy.19 A 
Cochrane review reported no difference in treatment with imiquimod com-
pared to placebo, based on data from two unpublished RCTs in 391 patients 
with cutaneous warts.20 On the other hand ICVT showed to inhibit other vi-
ruses such as herpes simplex and varicella zoster which makes it less plausi-
ble that the type of HPV influences this process.5 A second explanation might 
be related to treatment resistance. In the current study, 79% of patients had 
undergone a minimum of one previous treatment for AGW and 50% had un-
dergone 2-6 different previous treatments indicating treatment resistance. 
Knowing that warts were generally present for a long time (median of 3.8 
years), we can therefore anticipate that ICVT could have shown slight effica-
cy in subjects with recently developed, treatment-naive AGW. Dose or treat-
ment duration could also be responsible for the negative results of this trial, 
however these were similar to those in the previous cutaneous warts trial.
In conclusion, ICVT demonstrates to be safe to administer in patients 
with AGW but shows no pharmacodynamic activity or clinical efficacy after 6 
weeks of treatment. The observed lack of pharmacodynamic activity of ICVT 
in this early-phase clinical trial, involving viral load as a relevant biomarker, 
facilitates further rational drug selection for AGW and might therefore com-
press timelines for future drug development. 
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Figure 1. Schematic representation of the 3 main questions during the course of 
action of a drug. The first question enhances different aspects regarding reaching the 
site of action. We focused on one of these aspects; the administration of the drug (1) and 
developed an e-diary to measure the medication adherence of the patients in Chapter 
2. The second question entails demonstration of the mechanism of action of the drug 
by showing its pharmacological activity (2) and is investigated with the use of viral load 
measurements in chapter 4, 5 and 6. The third question refers to the clinical efficacy which 
is investigated using three-dimensional photography in chapter 3. This figure is adapted 
from S. de Visser 2003.1
The scope of this thesis was to develop and implement new methods for 
the monitoring of HPV-induced disease and to elucidate novel pharmaco-
logical interventions for these disorders. The overall disease burden of HPV 
infections is high. As responses to current treatments are poor and recur-
rence rates are high, there is a strong medical need for new, effective drugs 
that eliminates the virus with an acceptable side effect profile. A rational, 
question-based development approach that integrates the investigation of 
the pharmacological effects in early phase drug development, will obviously 
be consuming less time and resources. This approach was described in 2003 
in an attempt to efficiently investigate the pharmacological effects in early 
phase drug development.1 In this thesis, 3 main questions of this approach 
were applied to clinical drug development in HPV-induced diseases as shown 
in Figure 1:
1 Does the drug get to the site of action, i.e. is it administrated as 
prescribed? 
2 Does the compound cause its intended pharmacological effect?
3 Does the compound have beneficial effects on the disease?
It is essential to utilize the most appropriate methodology to answer these 
questions. Special attention was therefore given to the development of new 
methodological tools to monitor the course of HPV-related diseases in clini-
cal trials, as well as the exploration of successful biomarkers of viral load after 
HPV infections. In this thesis, studies that address different aspects of early 
clinical phase drug development in three different HPV-related diseases are 
presented. This thesis is divided into two parts: section 1 describes the devel-
opment and application of novel tools in clinical drug development and sec-
tion 2 focuses on early phase clinical studies examining safety, tolerability, 
pharmacodynamic and efficacy parameters of new topical compounds with 
high potential for the treatment of HPV-induced diseases. 
The current chapter provides a discussion of the results presented in this 
thesis and concerns: 1) the implementation of tools and biomarkers in early 
clinical trials in patients with HPV-induced disease, 2) the investigation of po-
tential novel medical treatments of HPV-induced diseases and 3) the implica-
tions of these findings for future clinical drug development in HPV-induced 
diseases.
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systemic circulation is necessary and even not desirable in case of digoxin for 
instance. The first question of the question-based drug development cannot 
be fully answered based on this research and as is shown in Figure 1 the first 
question entails several aspects, i.e. administration, absorption, distribution. 
Nevertheless, it is shown that the medication adherence is very high, impli-
cating that the drug is administrated on the lesions and based on the pre-
clinical studies it seems very likely that the drugs reached the sites of action. 
2. Does the compound cause its intended pharmacological effect?
The second question was investigated by the measurement of the pharma-
cological activity of the compound. The use of a biomarker can be helpful in 
the early phase of clinical drug development, as it can be used as a quantita-
tive indicator of a biological process.5 Multiple biomarkers have already been 
tested for the prediction of treatment success and the prognosis in patients 
with HPV-induced diseases.6-9 A useful biomarker 1) is easily applicable in 
clinical practice, 2) is reproducibly measurable over time, and 3) has a plau-
sible relation between the biomarker, the expected pharmacological effects 
and the pathogenesis of the disease. While the drugs of concern in this thesis 
are hypothesized to have anti-viral effects, we choose to measure viral load of 
the lesions. Previous research indicated that viral load is positively related to 
the severity of the disease; an increase of viral load in biopsies and cytologi-
cal samples of cervical lesions can predict the progression of the disease.10,11 
The gold standard to determine viral load is in biopsy samples, but these are 
invasive, remove (part of) the lesion and can only be performed for a limited 
number of times. Viral load can also be measured by taking a swab from the 
lesion, by rubbing the surface 5 consecutive times with a pre-wetted cotton-
tipped stick. It was already shown in 2011 that swabs of cutaneous warts (CW) 
can reliably identify the HPV genotype.12 In 2013, a study on genital lesions 
showed a high concordance between HPV genotyping by biopsy and swab in 
penile HSIL but only low to moderate concordance in AGW.13 Concordance of 
viral load measurements in swabs and biopsy samples has never been studied 
in HPV-induced diseases. It is also unknown whether the viral load measured 
with swabs can be used to evaluate HPV-induced diseases over time, i.e. dur-
ing treatment or follow-up. HPV genotyping and the determination of viral 
load of the lesions in HPV-induced diseases is of profound importance for 
the prediction of the drug efficacy and therefore may serve as a biomarker 
The development and implementation of tools 
and biomarkers in early clinical trials in pa-
tients with HPV-induced disease
1. Does the drug get to the site of action?
In order to get to an answer of the first question of the question-based ap-
proach we developed an e-diary to investigate the administration of the drug 
by treatment adherence. Most compounds for HPV-induced diseases are top-
ical drugs administered directly on the lesion by the patient himself at home. 
Importantly, medication adherence to long-term therapy is approximately 
50% and adherence to topical drugs is even poorer than oral treatments.2 
Chapter 2 described the development and implementation of the e-diary 
for the monitoring of treatment adherence and patient-reported outcomes 
in dermatological clinical trials to overcome the low adherence. The e-dia-
ry showed to be an excellent method to measure treatment administration 
as shown by the high treatment adherence rate (i.e. actual administrations 
divided by the expected administrations) of 98% (median; range 97-99%). 
E-diary adherence (i.e. actual entries divided by the expected entries) was 
also high with a median of 93% (range 87-97%) of photos capturing the applied 
drug. We hypothesized that this high adherence could have been the result of 
the designated reminder function of the e-diary to motivate patients to apply 
the drug on time. User acceptability of the e-diary was rated high by the pa-
tients as the e-diary was rated good to excellent by 89% of the patients and 
the user-friendliness was experienced as being good to excellent by 94% of 
the patients. Monitoring patient-reported outcomes by filling in daily symp-
tom scores provided good insights in the disease burden. Patients filled in the 
itch and pain score with a median adherence of 89% (range 87-96%) and 94% 
(range 87-96%), respectively. 
We can conclude that the e-diary seems a good tool to measure that the 
drug was applied on the lesions. Obviously it is not synonymous that the drug 
which is applied on the lesion also penetrates the skin or lesion and eventu-
ally accessing virally infected cells. However, animal models and in vitro ex-
periments using human donor skin showed that the drugs investigated in 
this thesis do sufficiently penetrate the skin.3,4 Also, the HPV-induced diseas-
es under investigation in this thesis are all restricted to cells above the basal 
layer, i.e. the epidermis. This means that no transdermal drug delivery to the 
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predict a treatment response. We hypothesize that the 3D camera seems to 
be an optimal candidate biomarker of HPV-induced lesions. Therefore, the 
use of 3D photography was validated and investigated in Chapter 3. Three-
dimensional photography with this specific camera system had an excellent 
accuracy and reproducibility. We also found a good to excellent agreement 
between different raters of the 3D photographs of the HPV-induced lesions. 
Caliper measurements of the dimensions of HPV-induced lesions are gold 
standard. We compared caliper and 3D measurements and found acceptable 
differences for the diameter of AGW, vulvar HSIL and CW and for the height of 
CW. Importantly, a difference between caliper and 3D measurements of the 
height of AGW lesions was found, probably because it was complicated to ac-
curately measure height with a caliper of these lesions in the genital area. We 
speculate that 3D photography is a more reliable method than caliper-based 
measurements although hard evidence remains to be obtained. By using 3D 
photography, one might be able to determine the efficacy of a drug in an early 
stage of drug development. Moreover, 3D photography serves as an excellent 
method to clinically visualize the HPV-induced lesions as it is accurate and 
precise and enables researchers to compare different time points at once. 
The 3D camera might also be useful for the measurement of lesion surface 
and volume, which enables an adequate prediction of drug efficacy. We were 
not able to validate surface and volume measurements by the 3D camera in 
AGW, vulvar HSIL and CW, as these could not be measured with a caliper due 
to the asymmetrical and irregular shape of these lesions. Nevertheless, 3D 
photography seems a more suitable and versatile method to measure these 
lesions. 
The investigation of potential novel medical 
treatments of HPV-induced diseases
In the second section of this thesis two potential novel topical treatments 
for different HPV-induced diseases were examined: I) omiganan and II) ionic 
contra-viral therapy (ICVT). Omiganan is an antimicrobial peptide with im-
munomodulatory and anti-viral properties and was investigated in patients 
with AGW and vulvar HSIL as described in Chapter 4. Omiganan showed to be 
safe for both indications as there were no serious adverse events and all ad-
verse events were of mild intensity and self-limiting. Omiganan significantly 
reduced viral load in AGW after 12 weeks of treatment once daily, but no clini-
cal efficacy was shown. In vulvar HSIL, omiganan did not reduce the viral load 
during clinical drug development.14 We implemented swabs to measure viral 
load in HPV-induced lesions over time in the trials described in Chapter 4, 5 
and 6. Although it was found that viral load in swabs was highly variable per 
patient we detected significant differences in viral load over time between 
the different treatment groups. In Chapter 4 we evaluated viral load in biop-
sies and swabs of CW and found a significant correlation between both meth-
ods. Also, there was a significant correlation between the wart size reduction 
and the reduction in HPV load. Unfortunately, in AGW and vulvar HSIL it was 
not possible to compare swabs with biopsies because other laboratory tech-
niques were used. Taking a swab is a noninvasive procedure that can be per-
formed in the same lesion over time, but the procedure is also sensitive and 
has to be performed reproducibly and accurately, e.g. rubbing harder of more 
often could result in the collection of more viral cells. Therefore, it is impor-
tant that the swab procedure is standardized and that all investigators use 
the same procedure. The implementation of this biomarker clarified wheth-
er the hypothesized working mechanism, i.e. anti-viral activity of the com-
pounds, was applicable. Taken together, the measurement of viral load by 
taking swabs appears to be a good method to test pharmacological effects, i.e. 
antiviral activity, on HPV-induced lesions. With this knowledge, indications 
showing no anti-viral activity should not be further investigated and drug 
development for these specific indications should be discontinued. This ap-
proach helps saving time and resources by the early prediction of pharmaco-
logical activity and will assist in efficient drug development. 
3. Does the compound have beneficial effects on the disease?
To determine the efficacy of a topical drug on HPV-induced lesions, it is im-
portant to frequently and precisely assess the lesions over time. For clini-
cians, it is often difficult to define the precise location and margins of le-
sions, especially in vulvar HSIL. Biomarkers can help visualizing the lesion 
for early detection and follow-up purposes.15 Three-dimensional (3D) pho-
tography appears to be a good candidate biomarker to obtain comprehensive 
insight into the dimensions of lesions. The use of three-dimensional pho-
tography is already widely integrated into plastic surgery and anthropome-
try practice, but not yet applied in early phase clinical trials on drug devel-
opment in HPV-induced diseases.16-18 In clinical trials based on drug devel-
opment, small changes in lesion morphology or dimensions might already 
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a premalignant lesion causes by high risk HPV types and can progress to vul-
var cancer. Analyses of complete genome sequences have shown that HPV16 
is more diverse with four variant lineages, compared to two variant lineages 
for HPV6.21,22 These differences and their oncogenic properties may point to-
wards the hypothesis that omiganan can interfere with the low-risk HPV type 
6 and 11, but may not be effective for high-risk HPV type 16. An explanation 
might be that high risk HPV types cause integration of the viral DNA into the 
human genome and overexpression of the E6 and E7 oncoproteins, which are 
not amenable to omiganan treatment. 
The location and lesion type might also be of importance when predicting 
treatment response, e.g. penetration of drug might be easier on the mucosa 
instead of on a cutaneous wart.
The implications of these findings for future 
clinical drug development in HPV-induced 
diseases
The question-based drug development approach is useful for the design and 
conduct of (early phase) clinical trials in HPV-induced diseases. As shown in 
this thesis, the e-diary is an adequate tool to measure treatment adherence 
and patient-reported outcomes. In addition to that, the e-diary could also 
stimulate timely use of medication. In future clinical trials, patient-reported 
outcomes need further investigation. Also, the e-diary might be highly valu-
able to adjust the treatment based on patient-reported outcomes in clinical 
practice. Integration of e-diaries in clinical practice is gaining increased at-
tention, for example in COPD patients where electronic questionnaires are 
developed to predict symptom-defined exacerbations.23 
Viral load measurement by using swabs is a suitable biomarker for the pre-
diction of the anti-viral pharmacological efficacy of the drug. Viral load in 
swabs and biopsies had a good correlation in CW patients and therefore the 
swabs can replace the biopsies for the measurement of viral load in CW. The 
comparison of the viral load of swabs and biopsies in AGW and vulvar HSIL 
needs to be further investigated in future studies. For future implementa-
tion of 3D photography, validation of surface and volume measurements is 
warranted and another system might be necessary for the irregular shapes 
of the genital area. 
We encountered some difficulties with the precise measurement of the 
vulvar HSIL dimensions with both caliper and 3D photography. Vulvar HSIL 
after 12 weeks of treatment and neither showed any clinical efficacy. ICVT is 
comprised of digoxin and furosemide and inhibits the potassium influx on 
which DNA viruses rely for replication. Safety and efficacy and in patients 
with CW was investigated in Chapter 5. ICVT was shown to be safe in pa-
tients with CW. ICVT treatment once daily for 6 weeks significantly reduced 
viral load and size of the CW. Chapter 6 describes a clinical trial with ICVT in 
patients with AGW which showed that ICVT was well tolerated as there were 
no clinically relevant safety findings and no serious adverse events. Contrary 
to the findings in CW, ICVT in AGW patients did not show any pharmacologi-
cal activity nor clinical efficacy. 
Difference in pharmacological activity between compounds 
It is interesting that viral load measurements showed that the compounds 
had varying pharmacological efficacy on the different HPV-induced lesions. 
Omiganan reduced viral load in AGW patients, but did not show any pharma-
cological activity in vulvar HSIL. ICVT showed to reduce viral load and wart 
size in CW, but showed no pharmacological activity in AGW. There are mul-
tiple hypotheses for these varying pharmacological effects in HPV-induced 
diseases.
HPV types are divided in different groups based on the alignment of the viral 
DNA. The HPV-induced diseases in this thesis are caused by HPV types from 
the Alpha genus type. Cutaneous warts are caused by low risk types HPV2, 27 
and 57, AGW mostly by low risk type HPV6, while vulvar HSIL is mostly caused 
by the high risk type HPV16. The phylogenetic tree of HPV (see Figure 3 in the 
introduction of this thesis) shows that these types are evolutionary differ-
ent.19 Previous research indicated that the HPV type can predict treatment 
response in patients with CW.20 It was found that HPV2 and HPV27 were asso-
ciated with a limited response to the treatment of plantar warts with mono-
chloroacetic acid or the combination of cryotherapy and salicylic acid. HPV1 
can be a predictor of the response to the treatment of plantar warts with the 
combination of cryotherapy and salicylic acid. It is plausible that the differ-
ence in treatment response was caused by the difference in the causative 
HPV type. 
We tested omiganan in AGW and vulvar HSIL. In AGW, treatment with 
omiganan reduced viral load, while in vulvar HSIL no effect was observed. 
AGW is a benign lesion caused by low risk HPV types, whereas vulvar HSIL is 
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is associated with a highly variable appearance and most of the time lesions 
have irregular and blurred borders and are difficult to recognize. In future 
drug development initiatives it would therefore be ideal to improve the vi-
sualization of these HPV-induced lesions, for example with a specific fluores-
cent ligand for HPV-induced lesions. Fluorescence imaging has well-known 
advantages in intraoperative settings. Particularly near-infrared (NIR) fluo-
rescence seems interesting to investigate HPV-induced lesions, as its light in-
creases tissue penetration depth up to 1 cm. A fluorescent agent can either be 
nonspecific or targeted at HPV positive cells for example. NIR fluorescence 
has already been widely investigated in cancer surgery for other indications, 
such as ovarian and colorectal cancer.24,25 Imaging using NIR fluorescence 
should be further investigated in HPV-induced diseases and will hopefully 
facilitate the measurement of vulvar HSIL and other lesions in early stage 
clinical research. In addition, NIR fluorescence can also be valuable in clini-
cal practice for lesion diagnosis and visualization during operations, to en-
sure total lesion removal.
In conclusion, in this thesis we implemented the question-based drug de-
velopment approach in clinical trials in HPV-induced diseases. This led to the 
implementation of 1) the e-diary to confirm whether the drug has reached the 
site of action, 2) viral load measurement by swabs to determine the pharma-
cological activity of the compound and 3) three-dimensional photography to 
investigate the efficacy of the compound. Together, the described tools and 
biomarkers might be of high value for a more efficient drug development in 
HPV-induced diseases. Also, four clinical trials were performed with the topi-
cal drug omiganan and ICVT in patients with different HPV-induced diseases. 
These trials showed that both drug have different pharmacological and clini-
cal efficacy depending on the HPV-induced disease.
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De klassieke ontwikkeling van nieuwe medicijnen kent verschillende fases 
van onderzoek, waarbij in de vroegere fase de veiligheid wordt onderzocht 
en pas in een latere fase de effectiviteit van het middel in patiënten. Dit heeft 
als gevolg dat een nieuw middel bij voorbaat een lage slagingskans heeft in de 
geneesmiddelen ontwikkeling omdat pas in een latere fase blijkt of het mid-
del effectief is voor een bepaalde ziekte. In dit proefschrift hebben we onder-
zocht of een vraag gerelateerde aanpak van geneesmiddelontwikkeling een 
efficiëntere aanpak zou kunnen zijn voor door HPV-geïnduceerde ziekten. 
Tijdens de studies hebben we de volgende vragen gesteld: 
1 Komt het middel aan op de plaats van werking, ofwel wordt het op de 
lesies aangebracht?
2 Heeft het middel de beoogde farmacologische werking? 
3 Heeft het middel gunstige effecten op de ziekte? 
Met deze aanpak konden wij nieuwe instrumenten ontwikkelen en invoe-
ren in de klinische studies die beschreven staan in dit proefschrift. In de 
toekomst kunnen deze bijdragen aan het verbeteren van de ontwikkeling 
van medicijnen en hopelijk aan meer effectieve behandelingen van HPV-
geïnduceerde aandoeningen.
Het elektronische dagboek
De eerste vraag van de vraag gerelateerde aanpak was: komt het middel aan op 
de plaats van werking? De meeste geneesmiddelen voor HPV-geïnduceerde 
ziekten worden direct op de lesies aangebracht. Het is bekend dat de thera-
pietrouw (de mate waarin patiënten zich houden aan de voorschriften voor 
het gebruik van geneesmiddelen) bij deze middelen erg laag is. We hebben 
een elektronisch dagboek (e-dagboek) ontwikkeld om te onderzoeken of pa-
tiënten het middel aanbrengen op de lesies (hoofdstuk 1). Het e-dagboek liet 
een hoge therapietrouw zien, mogelijk door een ingebouwde herinnering in 
het e-dagboek die de patiënten motiveerde om het middel op de afgespro-
ken tijd aan te brengen. Het e-dagboek werd door de patiënten als zeer ge-
bruiksvriendelijk ervaren. Ook konden patiënten met behulp van het e-dag-
boek symptomen van de ziekte rapporteren. We kunnen concluderen dat het 
e-dagboek een goed hulpmiddel is om te meten of het medicijn de plaats van 
werking bereikt, en kan leiden tot een betere therapietrouw. 
Dit proefschrift beschrijft een aantal klinische studies over aandoeningen 
veroorzaakt door het humaan papillomavirus (HPV). Deze studies gaan ten 
eerste over nieuwe instrumenten om de effectiviteit van geneesmiddelen 
te onderzoeken en ten tweede over twee nieuwe geneesmiddelen, die zijn 
getest in verschillende HPV-geïnduceerde ziektebeelden. Nieuwe behande-
lingen voor deze ziekten zijn noodzakelijk omdat de huidige behandelingen 
vaak onvoldoende werken en/of vervelende bijwerkingen hebben. Daarnaast 
zijn de beschikbare behandelingen geassocieerd met een hoge kans op terug-
keer van de ziekte.
HPV is een virus dat de epitheelcellen van de huid en slijmvliezen kan infec-
teren. Dit is in de meeste gevallen een asymptomatische infectie, maar een per-
sisterende (aanhoudende) infectie kan verschillende aandoeningen veroorza-
ken. De genetische samenstelling van HPV kan worden onderverdeeld in 
vroege (E1-E2, E4-E7) en late genen (L1-L2). De vroege genen zijn betrokken 
bij het tot stand komen van de infectie en de late genen bij de verspreiding 
van het virus. De verschillende types HPV worden onderverdeeld in 5 gro-
epen: Alfa, Bèta, Gamma, Mu en Nu. De Alfa groep is de grootste en omvat 
de seksueel overdraagbare types. HPV kan ook worden getypeerd als een laag-
risico of hoog-risico virus, dat respectievelijk goedaardige aandoeningen of 
(voorstadia van) kanker kan veroorzaken. In dit proefschrift worden 3 soorten 
door HPV geïnduceerde ziekten onderzocht: huidwratten, genitale wratten 
en vulvaire hooggradige squameuze intra-epitheliale lesies (vulvaire HSIL).
Huidwratten zijn goedaardig en worden in de meeste gevallen veroor-
zaakt door HPV type 1, 2, 27 en 57. Ze verdwijnen meestal spontaan binnen 2 
jaar na diagnose, maar kunnen veel fysieke en psychosociale klachten geven. 
Genitale wratten, voornamelijk veroorzaakt door HPV type 6, zijn zeer be-
smettelijk en is wereldwijd een van de meest voorkomende seksueel over-
draagbare aandoening (SOA). Genitale wratten kunnen klachten geven zoals 
pijn en jeuk, maar het voornaamste probleem is de psychosociale belasting 
van aangedane mensen. Vulvaire HSIL is een voorstadium van schaamlipkan-
ker en wordt veroorzaakt door hoog-risico HPV types, in de meeste gevallen 
HPV type 16. Veel voorkomende symptomen zijn jeuk en pijn, seksuele pro-
blemen en psychosociale klachten. 
Bovengenoemde HPV-geïnduceerde aandoeningen komen steeds vaker 
voor. Omdat de huidige behandelingen niet altijd werken en vervelende bij-
werkingen kunnen hebben, en vanwege de hoge kans op het terugkomen van 
de aandoeningen, is onderzoek naar nieuwe behandelingen noodzakelijk.
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kunnen worden voorspeld op basis van kleine veranderingen in de vorm of 
afmetingen van lesies. In hoofdstuk 3 is het gebruik van 3D fotografie onder-
zocht voor HPV-geïnduceerde lesies in de klinische studies beschreven in dit 
proefschrift. 3D fotografie liet een hoge nauwkeurigheid zien, ook als de fo-
to’s werden beoordeeld door verschillende personen. De gouden standaard 
voor het opmeten van lesies is een schuifmaat. De vergelijking van de schuif-
maat met 3D fotografie liet kleine verschillen zien voor het bepalen van de di-
ameter van huidwratten, genitale wratten en vulvaire HSIL en de hoogte van 
huidwratten. 3D fotografie blijkt ook toepasbaar voor het opmeten van de op-
pervlakte en het volume van lesies. Op grond van de beschreven studies kun-
nen we concluderen dat we met 3D fotografie de werkzaamheid van een mid-
del mogelijk al in een vroege klinische fase kunnen voorspellen.
Nieuwe behandelingen voor HPV-geïnduceerde 
ziekten
In dit proefschrift werden twee nieuwe geneesmiddelen voor de verschillen-
de HPV-geïnduceerde ziekten onderzocht: 1) omiganan en 2) ionische contra 
virale therapie (ICVT). 
Omiganan is een antimicrobieel peptide met immuunmodulerende en an-
tivirale eigenschappen en werd onderzocht bij patiënten met genitale wrat-
ten en vulvaire HSIL (hoofdstuk 4). Omiganan bleek veilig te zijn voor beide 
indicaties en verlaagde de virale lading bij patiënten met genitale wratten, 
maar niet bij patiënten met vulvaire HSIL. Dit middel zorgde bij beide indica-
ties echter niet voor een afname van de lesies. 
ICVT bestaat uit digoxine en furosemide en remt de kaliuminstroom die 
DNA-virussen nodig hebben om te kunnen delen. We onderzochten de vei-
ligheid en effectiviteit van ICVT bij patiënten met huidwratten (hoofdstuk 5) 
en vonden dat ICVT veilig gebruikt kon worden voor deze indicatie en leidde 
tot een verlaagde virale lading en een afname van de grootte van de huidwrat-
ten. Een vervolgstudie met ICVT in patiënten met genitale wratten (hoofd-
stuk 6) liet echter geen farmacologische activiteit en ook geen klinische ef-
fectiviteit zien van ICVT.
Conclusie en toekomstperspectieven 
De beschreven instrumenten in dit proefschrift kunnen van grote waarde zijn 
voor een efficiëntere ontwikkeling van geneesmiddelen voor de behandeling 
van HPV-geïnduceerde ziekten. De vier beschreven klinische onderzoeken 
Virale lading
De tweede vraag van de vraag gerelateerde aanpak was: heeft het middel 
de beoogde farmacologische werking? Het testen van de farmacologische 
werking van het middel helpt ons bij het voorspellen van de werkzaamheid. 
Hiervoor is de hoeveelheid van het virus in de lesies gemeten, ook wel virale 
lading genoemd. Dit zegt iets over hoe actief het virus aan het delen is. De be-
paling en monitoring van deze virale lading is van grote waarde voor de voor-
spelling van de werkzaamheid van een geneesmiddel. De gouden standaard 
voor het bepalen van de virale lading is een biopt, maar dit is een invasieve 
handeling die de plek (gedeeltelijk) wegneemt en slechts één of een beperkt 
aantal keren kan worden uitgevoerd. Een alternatieve methode is een huid 
uitstrijkje van de lesies. Eerder werd al aangetoond dat het huid uitstrijkje be-
trouwbaar kan laten zien welk HPV type er aanwezig is. Tot op heden is nog 
niet aangetoond hoe betrouwbaar de virale lading kan worden gemeten met 
een huid uitstrijkje, in vergelijking met een biopt. We hebben het huid uit-
strijkje in 3 verschillende klinische studies uitgevoerd (hoofdstuk 3, 4 en 5) 
en gevonden dat, ondanks dat de virale lading erg verschilde per patiënt, het 
huid uitstrijkje een goede weergave gaf van de virale lading voor en na ver-
schillende behandelingen over de tijd. Uit de studie met huidwratten bleek 
dat de virale lading gebaseerd op een biopt en een huid uitstrijkje vergelijk-
baar was. Het meten van de virale lading met een huid uitstrijkje lijkt dus een 
geschikte manier om de werkzaamheid van een middel te bepalen.
Driedimensionale (3D) fotografie
De derde en laatste vraag die we wilden beantwoorden, was: heeft het mid-
del gunstige effecten op de ziekte? Om de effectiviteit van een middel op 
HPV-geïnduceerde lesies te kunnen bepalen, is het belangrijk om de lesies 
nauwkeurig te meten over de tijd. Vooral bij vulvaire HSIL is het soms moei-
lijk om de precieze afmetingen van lesies te bepalen. Een instrument welke 
lesies beter kan visualiseren kan daarom van grote waarde zijn voor het ver-
volgen van de lesies tijdens de behandeling, maar ook voor de vroege detec-
tie van lesies. Driedimensionale (3D) fotografie kan mogelijk nauwkeurig in-
zicht geven in de afmetingen van lesies. 3D fotografie wordt al in verschillen-
de vakgebieden gebruikt, zoals in de plastische chirurgie, maar wordt nog 
niet toegepast voor de ontwikkeling van nieuwe geneesmiddelen voor HPV-
geïnduceerde lesies. Met 3D fotografie zou de effectiviteit mogelijk al vroeg 
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met de nieuwe middelen omiganan en ICVT bij patiënten met verschillende 
HPV-geïnduceerde ziekten toonden aan dat beide middelen een verschillen-
de farmacologische en klinische werkzaamheid hebben, afhankelijk van de 
HPV-geïnduceerde ziekte. 
In toekomstige klinische onderzoeken zullen de patiënt gerapporteerde 
symptomen in het e-dagboek verder onderzocht moeten worden en ook zal 
het e-dagboek van waarde kunnen zijn in de dagelijkse praktijk om de behan-
deling te optimaliseren. Voor de vergelijking van huid uitstrijkjes en biopten 
voor de bepaling van virale lading bij vulvaire HSIL en AGW zal nog meer on-
derzoek gedaan moeten worden om aan te tonen dat de biopten vervangen 
kunnen worden door huid uitstrijkjes. En voor implementatie van de 3D fo-
tografie is validatie van oppervlakte en volume in HPV-geïnduceerde lesies 
waardevol. Het bepalen van de afmetingen van vulvaire HSIL was zowel met 
de schuifmaat als de 3D fotografie soms lastig, voornamelijk door het variabe-
le uiterlijk van de lesies en de vaak onscherpe begrenzing. Het zou voor toe-
komstige klinische onderzoeken ideaal zijn om de visualisatie van deze les-
ies te verbeteren, bijvoorbeeld met een specifiek fluorescerend ligand. Het 
beter visualiseren van deze lesies zou zowel voordeel hebben tijdens klini-
sche onderzoeken als in de dagelijkse praktijk voor de diagnostiek en tijdens 
operatieve ingrepen. 
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Chapter 3 – Figure 1. 3D reconstruction of the twelve inch ruler (A) and wart-like object 
(B). Three-D reconstruction of the twelve inch ruler by the image reconstruction software 
(A), and the wart-like object in a 3D reconstruction with a heat-map showing the height of the 
object which is used for the 3D analysis (B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 – Figure 1. Genome organization of the Alpha papillomavirus HPV16. The 
genome is comprised of a long control region (LCR) and eight genes that are involved in the 
virus life cycle. This figure is adapted from de Sanjosé 2018 and Doorbar 2015.9,10 
 
 
Chapter 1 – Figure 2. The life cycle of a HPV infection. A diagrammatic representation of 
the skin is shown after infection with HPV. Often a micro-trauma of the epithelium allows 
the virus to infect cells in the basal layer of the epithelium (dotted arrow lines). In the basal 
epithelial cells the virions are internalized and the viral genomes are transferred to the 
nucleus (genome maintenance). The genome of the virus is replicated in the nucleus and 
hereafter the virus particles are produced and released. The involvement of the early and late 
genes is shown with the arrows next to the figure. This figure is adapted from Doorbar 2005.4 
 
Chapter 1 – Figure 3. Phylogenetic tree of human papilloma virus (HPV) demonstrating 
their evolutionary relationship. HPV types are divided in 5 different groups: Alpha (pink and 
yellow), Beta (green), Gamma (blue), Mu (purple) and Nu (lilac). The Alpha-papillomaviruses 
are subdivided as low-risk (yellow) and high-risk (pink) based on the benign or malignant 
potential of the virus, respectively. Cutaneous warts are caused by low-risk HPV types of the 
Alpha genus. Typical appearances of a common wart on the hand (left) and a plantar wart 
(right) are shown. Anogenital warts are also caused by low-risk HPV types of the Alpha genus, 
but these are phylogenetically different from the HPV types causing cutaneous warts as shown 
in the tree by the division of the branches. Anogenital warts on the penile shaft (upper) and 
under the foreskin (lower) are shown. High-risk HPV types of the Alpha genus (pink) cause 
vulvar high-grade squamous intraepithelial lesions (HSIL) with a high degree of variation in 
appearance, such as elevated hyperkeratotic white lesions (left) or red lesions (right). 
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Chapter 3 – Figure 2. Three-dimensional reconstruction by stereophotogrammetry.  
A representative lesion for all three HPV-induced lesions (cutaneous warts, anogenital warts 
and vulvar HSIL) with on the left the 2D photograph, in the middle the 3D reconstruction and 
on the right the heat map showing height differences and the manual contour around the 
lesion. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 – Figure 2. Photography assessments of lesions over time. Photography of a 
patient with angenital warts and vulvar HSIL, both patients were treated with omiganan. Pre-
dose (day 0) the lesions are clearly visible. Upon treatment, the genital warts clearly resolve (a) 
and the vulvar HSIL remained the same (c). The patient of picture 2a had total clearance of the 
genital warts at EOS, but a post-inflammatory hypopigmentation has occurred at the lesion 
site. Day 0 is before start of treatment, day 84 is at the end of treatment (EOT) and day 168 is at 
the end of study (EOS). 
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Chapter 5 – Figure 5. Histological representative cases of classical cutaneous viral 
warts. (a) Verruca vulgaris H&E low power view (50x) with architectural characteristic 
inturning of the elongated rete ridges, epidermal hyperplasia, papillomatosis, 
hypergranulosis, hyperkeratosis and columns of parakeratosis. (b) Verruca vulgaris H&E, 
detail view (200x): note koilocytes (arrowhead) and coarse granula (arrows) mostly in top 
layers (stratum granulosum). (c) H&E low power view (50x) of verruca plana with epidermal 
hyperplasia, hypergranulosis, hyperkeratosis, koilocytes in middle and upper layers. (d) 
verruca plana H&E, detail view (100x) note the absence of papillomatosis, parakeratosis and 
coarse granula. 
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Chapter 5 – Figure 3c. Photography assessments of a common wart of subject #6 
(digoxin+furosemide). (a) Analysis of the primary endpoint for the intention-to-treat 
population (N=79) was performed using a mixed model with treatment, time and treatment 
by time as fixed factors and subject as random factor. All statistical tests were two-tailed 
with α-level of 0.05. Results showed a statistically significant reduction of wart size in the 
digoxin+furosemide group compared to placebo (-2.5mm; 95% CI -4.9 to -0.1; p=0.04). Single 
treatment groups (digoxin vs placebo and furosemide versus placebo) showed no statistically 
significant effects (-1.5mm; 95% CI -3.9 to 0.9; p=0.21, and -1.1mm; 95% CI -3.4 to 1.3; p=0.38, 
respectively). Changes in diameter were most pronounced after EOT, as shown in Figure 3A. 
(b) In the analysis of all treated warts (N=139) a statistically significant wart size reduction 
was observed between each active treatment group and placebo (digoxin+furosemide versus 
placebo; -3.0mm; 95% CI -4.9 to -1.1; p=0.002, digoxin vs placebo -1.9mm; 95% CI -3.7 to -0.2; 
p=0.03, furosemide versus placebo -2.1mm; 95% CI -3.8 to -0.4; p=0.01). (c) A photography 
assessment of a treated wart in the digoxin+furosemide group.
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but these ar  phy ogen tically different from the HPV types causing cutaneous warts as shown 
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Chapter 4 – Figure 2. Photography a sessments f les ons over time. Ph tography of a 
patient with angenital warts and vulvar HSIL, both patients were treated with omiganan. Pre-
dos  (day 0) th lesions are cl arly visible. Upon treatment, the genit l wart  clearly resolve (a) 
and the vulvar HSIL rem in d the same (c). The pa ient of picture 2a h d total clearance of the 
genital warts at EOS, but a pos -inflammatory hypopigmentation has occurred at the lesion 
site. Day 0 is be o  s art of treatment, day 84 is at he end of treatment (EOT) and day 168 is at 
the end of study (EOS). 
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Chapter  – Figure 5. Histological representative cases of cl ssical cut neous viral 
warts. (a) Ve ruca vu garis H&E low power view (50x) wi h rchitectural characteristic 
in urning of the longated r te ridges, epidermal hyperplasi , papillomatosis, 
hypergranulosis, hyperkeratosis and columns of parakeratosis. (b) Ve ruca vulgaris H&E, 
detail view (200x): note koilocytes (arrowhead) and co rse granula (arrows) mostly in top 
layers (stratum granulosum). (c) H&E low power view (50x) of verruca plana with epidermal 
hyperplasia, hypergranulosis, hyperkeratosis, koilocyt s in middle and upper layers. (d) 
verruca plana H&E, detail view (100x) note the absence of papillomatosis, parakeratosis and 
co rse granula. 
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(digoxin+furosemide). (a) Analysis of the primary endpoint for the in ention-to-treat 
population (N=79) was performed using a mixed model with reatmen , time a d treatment 
by time as fixed factors and subject as random f ctor. All statistical tests were two-tailed 
with α-level of 0.05. Result  showed a statisti lly significa t reduc ion of wart size in the 
digoxin+fu semide group compared to placebo (-2.5mm; 95% CI -4.9 to -0.1; p=0.04). Single 
t eatment group (digoxin vs placebo an  furo emide versus placebo) howed no statistically 
significant effects (-1.5mm; 95% CI -3.9 to 0.9; p=0.21, and -1.1mm; 95% CI -3.4 to 1.3; p=0.38, 
respectiv ly). Changes in diameterwere most pronounced after EOT, as shown in Figure 3A. 
(b) In the nalysis of all treated warts (N=139) a statisti lly significant war  size reduction 
was obs rved between each active t eatment group and placebo (digoxin+furo emide versus 
placebo; -3.0mm; 95% CI -4.9 to -1.1; p=0.002, digoxin vs placebo -1.9mm; 95% CI -3.7 to -0.2; 
p=0.03, furo emide versus placebo -2.1mm; 95% CI -3.8 to -0.4; p=0.01). (c) A photography 
assessment of  trea ed wart in the digoxin+fu semide group.
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